{"transactions":[{"id":2417569,"issuer":{"id":2655,"kind":"organization","name":"NEUROCRINE BIOSCIENCES INC","symbol":"NBIX"},"owners":[{"id":130927,"kind":"person","name":"Grigoriadis Dimitri E.","position":1,"cik":"0001423838","reported_name":"Grigoriadis Dimitri E.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Research Officer"}}],"security":"Restricted Stock Unit","published_at":"2022-02-03T01:04:40.000Z","date":"2022-01-31","kind":"grant","acquired":true,"shares":4746,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F2","text":"Each Restricted Stock Unit represents a contingent right to receive one share of the Issuer Common Stock."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"The Restricted Stock Units will vest annually at 1/4 of the units vesting on each of January 31, 2023, January 31, 2024, January 31, 2025, and January 31, 2026."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F3","text":"The Restricted Stock Units will vest annually at 1/4 of the units vesting on each of January 31, 2023, January 31, 2024, January 31, 2025, and January 31, 2026."}],"balance_after":4746,"derivative":{"underlying":"Common Stock","underlying_shares":4746},"source":{"system":"sec-edgar","filing":"0001209191-22-006588","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/914475/000120919122006588/doc4.xml","form_type":"4"}},{"id":2417568,"issuer":{"id":2655,"kind":"organization","name":"NEUROCRINE BIOSCIENCES INC","symbol":"NBIX"},"owners":[{"id":130927,"kind":"person","name":"Grigoriadis Dimitri E.","position":1,"cik":"0001423838","reported_name":"Grigoriadis Dimitri E.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Research Officer"}}],"security":"Stock Option","published_at":"2022-02-03T01:04:40.000Z","date":"2022-01-31","kind":"grant","acquired":true,"shares":32319,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"Represents option of which 1/48th of the shares underlying the option becomes vested and exercisable on February 28, 2022 and an additional 1/48th of the shares underlying the option becomes vested and exercisable each month thereafter."}],"balance_after":32319,"derivative":{"exercise_price":79.02,"expiration_date":"2032-01-31","underlying":"Common Stock","underlying_shares":32319},"source":{"system":"sec-edgar","filing":"0001209191-22-006588","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/914475/000120919122006588/doc4.xml","form_type":"4"}},{"id":2544909,"issuer":{"id":2655,"kind":"organization","name":"NEUROCRINE BIOSCIENCES INC","symbol":"NBIX"},"owners":[{"id":130927,"kind":"person","name":"Grigoriadis Dimitri E.","position":1,"cik":"0001423838","reported_name":"Grigoriadis Dimitri E.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Research Officer"}}],"security":"Non-Qualified Stock Option","published_at":"2021-10-12T22:32:44.000Z","date":"2021-10-07","kind":"exercise","acquired":false,"shares":5000,"price":43.24,"value":216200.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"Option granted February 06, 2017 and vested monthly over four years."}],"balance_after":43400,"derivative":{"exercise_price":43.24,"expiration_date":"2027-02-06","underlying":"Common Stock","underlying_shares":5000},"source":{"system":"sec-edgar","filing":"0001209191-21-060281","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/914475/000120919121060281/doc4.xml","form_type":"4"}},{"id":2544908,"issuer":{"id":2655,"kind":"organization","name":"NEUROCRINE BIOSCIENCES INC","symbol":"NBIX"},"owners":[{"id":130927,"kind":"person","name":"Grigoriadis Dimitri E.","position":1,"cik":"0001423838","reported_name":"Grigoriadis Dimitri E.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Research Officer"}}],"security":"Common Stock","published_at":"2021-10-12T22:32:44.000Z","date":"2021-10-07","kind":"sale","acquired":false,"shares":5000,"price":104.852,"value":524260.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The disposition reported in this Form 4 was effected by a broker pursuant to instructions consistent with Rule 10b5-1 trading plan adopted by the Reporting Person at least 60 days prior to the transaction date in Box 3 above. Additionally, Issuer policy restricts the Reporting Person from amending or otherwise modifying any 10b5-1 trading plan subsequent to adoption of the plan."},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"Represents a weighted average sales price per share. These shares were sold in multiple transactions at prices ranging from $104.75 to $105.085. The Reporting Person has provided to the issuer, and will provide to any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range."}],"balance_after":82273,"source":{"system":"sec-edgar","filing":"0001209191-21-060281","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/914475/000120919121060281/doc4.xml","form_type":"4"}},{"id":2544907,"issuer":{"id":2655,"kind":"organization","name":"NEUROCRINE BIOSCIENCES INC","symbol":"NBIX"},"owners":[{"id":130927,"kind":"person","name":"Grigoriadis Dimitri E.","position":1,"cik":"0001423838","reported_name":"Grigoriadis Dimitri E.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Research Officer"}}],"security":"Common Stock","published_at":"2021-10-12T22:32:44.000Z","date":"2021-10-07","kind":"exercise","acquired":true,"shares":5000,"price":43.24,"value":216200.0,"ownership":{"direct":true},"balance_after":87273,"source":{"system":"sec-edgar","filing":"0001209191-21-060281","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/914475/000120919121060281/doc4.xml","form_type":"4"}},{"id":2544906,"issuer":{"id":2655,"kind":"organization","name":"NEUROCRINE BIOSCIENCES INC","symbol":"NBIX"},"owners":[{"id":130927,"kind":"person","name":"Grigoriadis Dimitri E.","position":1,"cik":"0001423838","reported_name":"Grigoriadis Dimitri E.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Research Officer"}}],"security":"Common Stock","published_at":"2021-10-12T22:32:44.000Z","date":"2021-10-07","kind":"sale","acquired":false,"shares":3000,"price":104.7501,"value":314250.3,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The disposition reported in this Form 4 was effected by a broker pursuant to instructions consistent with Rule 10b5-1 trading plan adopted by the Reporting Person at least 60 days prior to the transaction date in Box 3 above. Additionally, Issuer policy restricts the Reporting Person from amending or otherwise modifying any 10b5-1 trading plan subsequent to adoption of the plan."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"Represents a weighted average sales price per share. These shares were sold in multiple transactions at prices ranging from $104.75 to $104.755. The Reporting Person has provided to the issuer, and will provide to any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range."}],"balance_after":82273,"source":{"system":"sec-edgar","filing":"0001209191-21-060281","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/914475/000120919121060281/doc4.xml","form_type":"4"}},{"id":2769848,"issuer":{"id":2655,"kind":"organization","name":"NEUROCRINE BIOSCIENCES INC","symbol":"NBIX"},"owners":[{"id":130927,"kind":"person","name":"Grigoriadis Dimitri E.","position":1,"cik":"0001423838","reported_name":"Grigoriadis Dimitri E.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Research Officer"}}],"security":"Stock Option","published_at":"2021-03-29T10:21:24.000Z","date":"2021-02-08","kind":"grant","acquired":true,"shares":42042,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"Represents option of which 1/48th of the shares underlying the option becomes vested and exercisable on March 8, 2021 and an additional 1/48th of the shares underlying the option becomes vested and exercisable each month thereafter."}],"balance_after":42042,"derivative":{"exercise_price":117.63,"expiration_date":"2031-02-08","underlying":"Common Stock","underlying_shares":42042},"source":{"system":"sec-edgar","filing":"0001209191-21-023381","document":"doc4a.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/914475/000120919121023381/doc4a.xml","form_type":"4/A","original_submission_date":"2021-02-09"}},{"id":2872945,"issuer":{"id":2655,"kind":"organization","name":"NEUROCRINE BIOSCIENCES INC","symbol":"NBIX"},"owners":[{"id":130927,"kind":"person","name":"Grigoriadis Dimitri E.","position":1,"cik":"0001423838","reported_name":"Grigoriadis Dimitri E.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Research Officer"}}],"security":"Restricted Stock Unit","published_at":"2021-02-10T02:18:48.000Z","date":"2021-02-08","kind":"grant","acquired":true,"shares":6376,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F10","text":"Each Restricted Stock Unit represents a contingent right to receive one share of the Issuer Common Stock."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F11","text":"The Restricted Stock Units will vest annually at 1/4 of the units vesting on each of February 8, 2022, February 8, 2023, February 8, 2024, and February 8, 2025."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F11","text":"The Restricted Stock Units will vest annually at 1/4 of the units vesting on each of February 8, 2022, February 8, 2023, February 8, 2024, and February 8, 2025."}],"balance_after":6376,"derivative":{"underlying":"Common Stock","underlying_shares":6376},"source":{"system":"sec-edgar","filing":"0001209191-21-009119","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":6,"url":"https://www.sec.gov/Archives/edgar/data/914475/000120919121009119/doc4.xml","form_type":"4"}},{"id":2872944,"issuer":{"id":2655,"kind":"organization","name":"NEUROCRINE BIOSCIENCES INC","symbol":"NBIX"},"owners":[{"id":130927,"kind":"person","name":"Grigoriadis Dimitri E.","position":1,"cik":"0001423838","reported_name":"Grigoriadis Dimitri E.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Research Officer"}}],"security":"Stock Option","published_at":"2021-02-10T02:18:48.000Z","date":"2021-02-08","kind":"grant","acquired":true,"shares":38256,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F9","text":"Represents option of which 1/48th of the shares underlying the option becomes vested and exercisable on March 8, 2021 and an additional 1/48th of the shares underlying the option becomes vested and exercisable each month thereafter."}],"balance_after":38256,"derivative":{"exercise_price":117.63,"expiration_date":"2031-02-08","underlying":"Common Stock","underlying_shares":38256},"source":{"system":"sec-edgar","filing":"0001209191-21-009119","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/914475/000120919121009119/doc4.xml","form_type":"4"}},{"id":2872943,"issuer":{"id":2655,"kind":"organization","name":"NEUROCRINE BIOSCIENCES INC","symbol":"NBIX"},"owners":[{"id":130927,"kind":"person","name":"Grigoriadis Dimitri E.","position":1,"cik":"0001423838","reported_name":"Grigoriadis Dimitri E.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Research Officer"}}],"security":"Common Stock","published_at":"2021-02-10T02:18:48.000Z","date":"2021-02-08","kind":"sale","acquired":false,"shares":1218,"price":116.7014,"value":142142.3052,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F7","text":"Sale of 1,218 shares of common stock issued upon vesting of 2,313 restricted stock units on February 8, 2021 to cover payroll and withholding taxes, with the balance of the shares (1,095) maintained by the Reporting Person; the disposition reported in this Form 4 was effected by a broker pursuant to instructions set forth in a Rule 10b5-1 trading plan adopted by the Reporting Person at least 60 days prior to the transaction date in Box 3 above. Additionally, Issuer policy restricts the Reporting Person from amending or otherwise modifying any 10b5-1 trading plan subsequent to adoption of the plan."},{"field":"price","element":"transactionPricePerShare","label":"F8","text":"Represents a weighted average sales price per share. These shares were sold in multiple transactions at prices ranging from $116.01 to $117.20. The Reporting Person has provided to the issuer, and will provide to any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range."}],"balance_after":85273,"source":{"system":"sec-edgar","filing":"0001209191-21-009119","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/914475/000120919121009119/doc4.xml","form_type":"4"}},{"id":2872942,"issuer":{"id":2655,"kind":"organization","name":"NEUROCRINE BIOSCIENCES INC","symbol":"NBIX"},"owners":[{"id":130927,"kind":"person","name":"Grigoriadis Dimitri E.","position":1,"cik":"0001423838","reported_name":"Grigoriadis Dimitri E.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Research Officer"}}],"security":"Common Stock","published_at":"2021-02-10T02:18:48.000Z","date":"2021-02-08","kind":"sale","acquired":false,"shares":803,"price":116.6938,"value":93705.1214,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F5","text":"Sale of 803 shares of common stock issued upon vesting of 1,525 restricted stock units on February 8, 2021 to cover payroll and withholding taxes, with the balance of the shares (722) maintained by the Reporting Person; the disposition reported in this Form 4 was effected by a broker pursuant to instructions set forth in a Rule 10b5-1 trading plan adopted by the Reporting Person at least 60 days prior to the transaction date in Box 3 above. Additionally, Issuer policy restricts the Reporting Person from amending or otherwise modifying any 10b5-1 trading plan subsequent to adoption of the plan."},{"field":"price","element":"transactionPricePerShare","label":"F6","text":"Represents a weighted average sales price per share. These shares were sold in multiple transactions at prices ranging from $116.01 to $117.71. The Reporting Person has provided to the issuer, and will provide to any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range."}],"balance_after":84178,"source":{"system":"sec-edgar","filing":"0001209191-21-009119","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/914475/000120919121009119/doc4.xml","form_type":"4"}},{"id":2872941,"issuer":{"id":2655,"kind":"organization","name":"NEUROCRINE BIOSCIENCES INC","symbol":"NBIX"},"owners":[{"id":130927,"kind":"person","name":"Grigoriadis Dimitri E.","position":1,"cik":"0001423838","reported_name":"Grigoriadis Dimitri E.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Research Officer"}}],"security":"Common Stock","published_at":"2021-02-10T02:18:48.000Z","date":"2021-02-08","kind":"sale","acquired":false,"shares":687,"price":116.6693,"value":80151.8091,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F3","text":"Sale of 687 shares of common stock issued upon vesting of 1,974 restricted stock units on February 8, 2021 to cover payroll and withholding taxes, with the balance of the shares (1,287) maintained by the Reporting Person. The disposition reported in this Form 4 was effected by a broker pursuant to instructions consistent with Rule 10b5-1 at least 60 days prior to the transaction date in Box 3 above."},{"field":"price","element":"transactionPricePerShare","label":"F4","text":"Represents a weighted average sales price per share. These shares were sold in multiple transactions at prices ranging from $115.97 to $117.20. The Reporting Person has provided to the issuer, and will provide to any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range."}],"balance_after":83456,"source":{"system":"sec-edgar","filing":"0001209191-21-009119","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/914475/000120919121009119/doc4.xml","form_type":"4"}},{"id":2872940,"issuer":{"id":2655,"kind":"organization","name":"NEUROCRINE BIOSCIENCES INC","symbol":"NBIX"},"owners":[{"id":130927,"kind":"person","name":"Grigoriadis Dimitri E.","position":1,"cik":"0001423838","reported_name":"Grigoriadis Dimitri E.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Research Officer"}}],"security":"Common Stock","published_at":"2021-02-10T02:18:48.000Z","date":"2021-02-05","kind":"sale","acquired":false,"shares":605,"price":113.7563,"value":68822.5615,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Sale of 605 shares of common stock issued upon vesting of 1,150 restricted stock units on February 5, 2021 to cover payroll and withholding taxes, with the balance of the shares (545) maintained by the Reporting Person; the disposition reported in this Form 4 was effected by a broker pursuant to instructions set forth in a Rule 10b5-1 trading plan adopted by the Reporting Person at least 60 days prior to the transaction date in Box 3 above. Additionally, Issuer policy restricts the Reporting Person from amending or otherwise modifying any 10b5-1 trading plan subsequent to adoption of the plan."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"Represents a weighted average sales price per share. These shares were sold in multiple transactions at prices ranging from $111.81 to $116.26. The Reporting Person has provided to the issuer, and will provide to any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range."}],"balance_after":82169,"source":{"system":"sec-edgar","filing":"0001209191-21-009119","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/914475/000120919121009119/doc4.xml","form_type":"4"}},{"id":2980249,"issuer":{"id":2655,"kind":"organization","name":"NEUROCRINE BIOSCIENCES INC","symbol":"NBIX"},"owners":[{"id":130927,"kind":"person","name":"Grigoriadis Dimitri E.","position":1,"cik":"0001423838","reported_name":"Grigoriadis Dimitri E.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Research Officer"}}],"security":"Common Stock","published_at":"2020-11-16T23:19:03.000Z","date":"2020-11-12","kind":"sale","acquired":false,"shares":2257,"price":90.7327,"value":204783.7039,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Sale of 2,257 shares of common stock issued upon vesting of 4,288 performance restricted stock units to cover withholding taxes, with the balance of the shares (2,031) maintained by the Reporting Person; the disposition reported in this Form 4 was effected by a broker pursuant to instructions set forth in a Rule 10b5-1 trading plan adopted by the Reporting Person at least 60 days prior to the transaction date in Box 3 above. Additionally, Issuer policy restricts the Reporting Person from amending or otherwise modifying any 10b5-1 trading plan subsequent to adoption of the plan."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"Represents a weighted average sales price per share. These shares were sold in multiple transactions at prices ranging from $88.93 to $92.27. The Reporting Person has provided to the issuer, and will provide to any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range."}],"balance_after":81624,"source":{"system":"sec-edgar","filing":"0001209191-20-058547","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/914475/000120919120058547/doc4.xml","form_type":"4"}},{"id":3065175,"issuer":{"id":2655,"kind":"organization","name":"NEUROCRINE BIOSCIENCES INC","symbol":"NBIX"},"owners":[{"id":130927,"kind":"person","name":"Grigoriadis Dimitri E.","position":1,"cik":"0001423838","reported_name":"Grigoriadis Dimitri E.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Research Officer"}}],"security":"Common Stock","published_at":"2020-08-07T23:36:14.000Z","date":"2020-08-05","kind":"sale","acquired":false,"shares":2257,"price":118.8302,"value":268199.7614,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Sale of 2,257 shares of common stock issued upon vesting of 4,287 performance restricted stock units to cover withholding\ntaxes, with the balance of the shares (2,030) maintained by the Reporting Person. The disposition reported in this Form 4 was effected by a\nbroker pursuant to instructions set forth in a Rule 10b5-1 trading plan adopted by the Reporting Person at least 60 days prior to the transaction\ndate in Box 3 above. Additionally, Issuer policy restricts the Reporting Person from amending or otherwise modifying any 10b5-1 trading plan\nsubsequent to adoption of the plan."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"Represents a weighted average sales price per share. These shares were sold in multiple transactions at prices ranging from $118.29 to $120.56. The Reporting Person has provided to the issuer, and will provide to any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range."}],"balance_after":79593,"source":{"system":"sec-edgar","filing":"0001209191-20-045758","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/914475/000120919120045758/doc4.xml","form_type":"4"}},{"id":3111013,"issuer":{"id":2655,"kind":"organization","name":"NEUROCRINE BIOSCIENCES INC","symbol":"NBIX"},"owners":[{"id":130927,"kind":"person","name":"Grigoriadis Dimitri E.","position":1,"cik":"0001423838","reported_name":"Grigoriadis Dimitri E.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Research Officer"}}],"security":"Incentive Stock Option","published_at":"2020-06-15T21:31:57.000Z","date":"2020-06-11","kind":"exercise","acquired":false,"shares":1049,"price":43.24,"value":45358.76,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"Option granted February 6, 2017 and vests monthly over four years."}],"balance_after":2151,"derivative":{"exercise_price":43.24,"expiration_date":"2027-02-06","underlying":"Common Stock","underlying_shares":1049},"source":{"system":"sec-edgar","filing":"0001209191-20-036698","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":6,"url":"https://www.sec.gov/Archives/edgar/data/914475/000120919120036698/doc4.xml","form_type":"4"}},{"id":3111012,"issuer":{"id":2655,"kind":"organization","name":"NEUROCRINE BIOSCIENCES INC","symbol":"NBIX"},"owners":[{"id":130927,"kind":"person","name":"Grigoriadis Dimitri E.","position":1,"cik":"0001423838","reported_name":"Grigoriadis Dimitri E.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Research Officer"}}],"security":"Incentive Stock Option","published_at":"2020-06-15T21:31:57.000Z","date":"2020-06-11","kind":"exercise","acquired":false,"shares":1812,"price":35.99,"value":65213.88,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"Option granted February 5, 2016 and vested monthly over four years."}],"balance_after":0,"derivative":{"exercise_price":35.99,"expiration_date":"2026-02-05","underlying":"Common Stock","underlying_shares":1812},"source":{"system":"sec-edgar","filing":"0001209191-20-036698","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/914475/000120919120036698/doc4.xml","form_type":"4"}},{"id":3111011,"issuer":{"id":2655,"kind":"organization","name":"NEUROCRINE BIOSCIENCES INC","symbol":"NBIX"},"owners":[{"id":130927,"kind":"person","name":"Grigoriadis Dimitri E.","position":1,"cik":"0001423838","reported_name":"Grigoriadis Dimitri E.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Research Officer"}}],"security":"Incentive Stock Option","published_at":"2020-06-15T21:31:57.000Z","date":"2020-06-11","kind":"exercise","acquired":false,"shares":2710,"price":32.99,"value":89402.9,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"Option granted February 3, 2015 and vested monthly over four years."}],"balance_after":0,"derivative":{"exercise_price":32.99,"expiration_date":"2025-02-03","underlying":"Common Stock","underlying_shares":2710},"source":{"system":"sec-edgar","filing":"0001209191-20-036698","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/914475/000120919120036698/doc4.xml","form_type":"4"}},{"id":3111010,"issuer":{"id":2655,"kind":"organization","name":"NEUROCRINE BIOSCIENCES INC","symbol":"NBIX"},"owners":[{"id":130927,"kind":"person","name":"Grigoriadis Dimitri E.","position":1,"cik":"0001423838","reported_name":"Grigoriadis Dimitri E.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Research Officer"}}],"security":"Common Stock","published_at":"2020-06-15T21:31:57.000Z","date":"2020-06-11","kind":"exercise","acquired":true,"shares":1049,"price":43.24,"value":45358.76,"ownership":{"direct":true},"balance_after":77563,"source":{"system":"sec-edgar","filing":"0001209191-20-036698","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/914475/000120919120036698/doc4.xml","form_type":"4"}},{"id":3111009,"issuer":{"id":2655,"kind":"organization","name":"NEUROCRINE BIOSCIENCES INC","symbol":"NBIX"},"owners":[{"id":130927,"kind":"person","name":"Grigoriadis Dimitri E.","position":1,"cik":"0001423838","reported_name":"Grigoriadis Dimitri E.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Research Officer"}}],"security":"Common Stock","published_at":"2020-06-15T21:31:57.000Z","date":"2020-06-11","kind":"exercise","acquired":true,"shares":1812,"price":35.99,"value":65213.88,"ownership":{"direct":true},"balance_after":76514,"source":{"system":"sec-edgar","filing":"0001209191-20-036698","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/914475/000120919120036698/doc4.xml","form_type":"4"}},{"id":3111008,"issuer":{"id":2655,"kind":"organization","name":"NEUROCRINE BIOSCIENCES INC","symbol":"NBIX"},"owners":[{"id":130927,"kind":"person","name":"Grigoriadis Dimitri E.","position":1,"cik":"0001423838","reported_name":"Grigoriadis Dimitri E.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Research Officer"}}],"security":"Common Stock","published_at":"2020-06-15T21:31:57.000Z","date":"2020-06-11","kind":"exercise","acquired":true,"shares":2710,"price":32.99,"value":89402.9,"ownership":{"direct":true},"balance_after":74702,"source":{"system":"sec-edgar","filing":"0001209191-20-036698","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/914475/000120919120036698/doc4.xml","form_type":"4"}},{"id":3141491,"issuer":{"id":2655,"kind":"organization","name":"NEUROCRINE BIOSCIENCES INC","symbol":"NBIX"},"owners":[{"id":130927,"kind":"person","name":"Grigoriadis Dimitri E.","position":1,"cik":"0001423838","reported_name":"Grigoriadis Dimitri E.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Research Officer"}}],"security":"Non-Qualified Stock Option","published_at":"2020-05-20T22:59:39.000Z","date":"2020-05-19","kind":"exercise","acquired":false,"shares":10000,"price":35.99,"value":359900.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"Option granted February 5, 2016 and vested monthly over four years."}],"balance_after":9588,"derivative":{"exercise_price":35.99,"expiration_date":"2026-02-05","underlying":"Common Stock","underlying_shares":10000},"source":{"system":"sec-edgar","filing":"0001209191-20-031028","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":7,"url":"https://www.sec.gov/Archives/edgar/data/914475/000120919120031028/doc4.xml","form_type":"4"}},{"id":3141490,"issuer":{"id":2655,"kind":"organization","name":"NEUROCRINE BIOSCIENCES INC","symbol":"NBIX"},"owners":[{"id":130927,"kind":"person","name":"Grigoriadis Dimitri E.","position":1,"cik":"0001423838","reported_name":"Grigoriadis Dimitri E.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Research Officer"}}],"security":"Non-Qualified Stock Option","published_at":"2020-05-20T22:59:39.000Z","date":"2020-05-18","kind":"exercise","acquired":false,"shares":10000,"price":35.99,"value":359900.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"Option granted February 5, 2016 and vested monthly over four years."}],"balance_after":19588,"derivative":{"exercise_price":35.99,"expiration_date":"2026-02-05","underlying":"Common Stock","underlying_shares":10000},"source":{"system":"sec-edgar","filing":"0001209191-20-031028","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":6,"url":"https://www.sec.gov/Archives/edgar/data/914475/000120919120031028/doc4.xml","form_type":"4"}},{"id":3141489,"issuer":{"id":2655,"kind":"organization","name":"NEUROCRINE BIOSCIENCES INC","symbol":"NBIX"},"owners":[{"id":130927,"kind":"person","name":"Grigoriadis Dimitri E.","position":1,"cik":"0001423838","reported_name":"Grigoriadis Dimitri E.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Research Officer"}}],"security":"Common Stock","published_at":"2020-05-20T22:59:39.000Z","date":"2020-05-19","kind":"sale","acquired":false,"shares":32749,"price":126.7255,"value":4150133.3995,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The disposition reported in this Form 4 was effected by a broker pursuant to instructions set forth in a Rule 10b5-1 trading plan adopted by the Reporting Person at least 60 days prior to the transaction date in Box 3 above. Additionally, Issuer policy restricts the Reporting Person from amending or otherwise modifying any 10b5-1 trading plan subsequent to adoption of the plan."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"Represents a weighted average sales price per share. These shares were sold in multiple transactions at prices ranging from $125.91 to $127.25. The Reporting Person has provided to the issuer, and will provide to any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range."}],"balance_after":71992,"source":{"system":"sec-edgar","filing":"0001209191-20-031028","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/914475/000120919120031028/doc4.xml","form_type":"4"}},{"id":3141488,"issuer":{"id":2655,"kind":"organization","name":"NEUROCRINE BIOSCIENCES INC","symbol":"NBIX"},"owners":[{"id":130927,"kind":"person","name":"Grigoriadis Dimitri E.","position":1,"cik":"0001423838","reported_name":"Grigoriadis Dimitri E.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Research Officer"}}],"security":"Common Stock","published_at":"2020-05-20T22:59:39.000Z","date":"2020-05-19","kind":"sale","acquired":false,"shares":10000,"price":125.98,"value":1259800.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The disposition reported in this Form 4 was effected by a broker pursuant to instructions set forth in a Rule 10b5-1 trading plan adopted by the Reporting Person at least 60 days prior to the transaction date in Box 3 above. Additionally, Issuer policy restricts the Reporting Person from amending or otherwise modifying any 10b5-1 trading plan subsequent to adoption of the plan."}],"balance_after":104741,"source":{"system":"sec-edgar","filing":"0001209191-20-031028","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/914475/000120919120031028/doc4.xml","form_type":"4"}},{"id":3141487,"issuer":{"id":2655,"kind":"organization","name":"NEUROCRINE BIOSCIENCES INC","symbol":"NBIX"},"owners":[{"id":130927,"kind":"person","name":"Grigoriadis Dimitri E.","position":1,"cik":"0001423838","reported_name":"Grigoriadis Dimitri E.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Research Officer"}}],"security":"Common Stock","published_at":"2020-05-20T22:59:39.000Z","date":"2020-05-19","kind":"exercise","acquired":true,"shares":10000,"price":35.99,"value":359900.0,"ownership":{"direct":true},"balance_after":114741,"source":{"system":"sec-edgar","filing":"0001209191-20-031028","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/914475/000120919120031028/doc4.xml","form_type":"4"}},{"id":3141486,"issuer":{"id":2655,"kind":"organization","name":"NEUROCRINE BIOSCIENCES INC","symbol":"NBIX"},"owners":[{"id":130927,"kind":"person","name":"Grigoriadis Dimitri E.","position":1,"cik":"0001423838","reported_name":"Grigoriadis Dimitri E.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Research Officer"}}],"security":"Common Stock","published_at":"2020-05-20T22:59:39.000Z","date":"2020-05-18","kind":"sale","acquired":false,"shares":10000,"price":119.98,"value":1199800.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The disposition reported in this Form 4 was effected by a broker pursuant to instructions set forth in a Rule 10b5-1 trading plan adopted by the Reporting Person at least 60 days prior to the transaction date in Box 3 above. Additionally, Issuer policy restricts the Reporting Person from amending or otherwise modifying any 10b5-1 trading plan subsequent to adoption of the plan."}],"balance_after":104741,"source":{"system":"sec-edgar","filing":"0001209191-20-031028","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/914475/000120919120031028/doc4.xml","form_type":"4"}},{"id":3141485,"issuer":{"id":2655,"kind":"organization","name":"NEUROCRINE BIOSCIENCES INC","symbol":"NBIX"},"owners":[{"id":130927,"kind":"person","name":"Grigoriadis Dimitri E.","position":1,"cik":"0001423838","reported_name":"Grigoriadis Dimitri E.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Research Officer"}}],"security":"Common Stock","published_at":"2020-05-20T22:59:39.000Z","date":"2020-05-18","kind":"exercise","acquired":true,"shares":10000,"price":35.99,"value":359900.0,"ownership":{"direct":true},"balance_after":114741,"source":{"system":"sec-edgar","filing":"0001209191-20-031028","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/914475/000120919120031028/doc4.xml","form_type":"4"}},{"id":3155165,"issuer":{"id":2655,"kind":"organization","name":"NEUROCRINE BIOSCIENCES INC","symbol":"NBIX"},"owners":[{"id":130927,"kind":"person","name":"Grigoriadis Dimitri E.","position":1,"cik":"0001423838","reported_name":"Grigoriadis Dimitri E.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Research Officer"}}],"security":"Common Stock","published_at":"2020-05-12T00:06:03.000Z","date":"2020-05-07","kind":"sale","acquired":false,"shares":8682,"price":105.4428,"value":915454.3896,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The disposition reported in this Form 4 was effected by a broker pursuant to instructions set forth in a Rule 10b5-1 trading plan adopted by the Reporting Person at least 60 days prior to the transaction date in Box 3 above. Additionally, Issuer policy restricts the Reporting Person from amending or otherwise modifying any 10b5-1 trading plan subsequent to adoption of the plan."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"Represents a weighted average sales price per share. These shares were sold in multiple transactions at prices ranging from $105.00 to $106.20. The Reporting Person has provided to the issuer, and will provide to any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range."}],"balance_after":104741,"source":{"system":"sec-edgar","filing":"0001209191-20-028392","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/914475/000120919120028392/doc4.xml","form_type":"4"}},{"id":3168578,"issuer":{"id":2655,"kind":"organization","name":"NEUROCRINE BIOSCIENCES INC","symbol":"NBIX"},"owners":[{"id":130927,"kind":"person","name":"Grigoriadis Dimitri E.","position":1,"cik":"0001423838","reported_name":"Grigoriadis Dimitri E.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Research Officer"}}],"security":"Common Stock","published_at":"2020-04-29T00:42:31.000Z","date":"2020-04-24","kind":"sale","acquired":false,"shares":1934,"price":99.4096,"value":192258.1664,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Sale of 1,934 shares of common stock issued upon vesting of 3,675 performance restricted stock units on April 24, 2020 to cover withholding taxes, with the balance of the shares (1,741) maintained by the Reporting Person; the disposition reported in this Form 4 was effected by a broker pursuant to instructions set forth in a Rule 10b5-1 trading plan adopted by the Reporting Person at least 60 days prior to the transaction date in Box 3 above. Additionally, Issuer policy restricts the Reporting Person from amending or otherwise modifying any 10b5-1 trading plan subsequent to adoption of the plan."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"Represents a weighted average sales price per share. These shares were sold in multiple transactions at prices ranging from $97.56 to $101.13. The Reporting Person has provided to the issuer, and will provide to any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range."}],"balance_after":113423,"source":{"system":"sec-edgar","filing":"0001209191-20-026069","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/914475/000120919120026069/doc4.xml","form_type":"4"}},{"id":3280435,"issuer":{"id":2655,"kind":"organization","name":"NEUROCRINE BIOSCIENCES INC","symbol":"NBIX"},"owners":[{"id":130927,"kind":"person","name":"Grigoriadis Dimitri E.","position":1,"cik":"0001423838","reported_name":"Grigoriadis Dimitri E.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Research Officer"}}],"security":"Common Stock","published_at":"2020-02-12T00:16:46.000Z","date":"2020-02-07","kind":"sale","acquired":false,"shares":1218,"price":103.3108,"value":125832.5544,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Sale of 1,218 shares of common stock issued upon vesting of 2,313 restricted stock units on February 7, 2020 to cover payroll and withholding taxes, with the balance of the shares (1,095) maintained by the Reporting Person; the disposition reported in this Form 4 was effected by a broker pursuant to instructions set forth in a Rule 10b5-1 trading plan adopted by the Reporting Person at least 90 days prior to the transaction date in Box 2 above. Additionally, Issuer policy restricts the Reporting Person from amending or otherwise modifying any 10b5-1 trading plan subsequent to adoption of the plan."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"Represents a weighted average sales price per share. These shares were sold in multiple transactions at prices ranging from $102.23 to $104.14. The Reporting Person has provided to the issuer, and will provide to any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range."}],"balance_after":111682,"source":{"system":"sec-edgar","filing":"0001209191-20-008498","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/914475/000120919120008498/doc4.xml","form_type":"4"}},{"id":3285296,"issuer":{"id":2655,"kind":"organization","name":"NEUROCRINE BIOSCIENCES INC","symbol":"NBIX"},"owners":[{"id":130927,"kind":"person","name":"Grigoriadis Dimitri E.","position":1,"cik":"0001423838","reported_name":"Grigoriadis Dimitri E.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Research Officer"}}],"security":"Restricted Stock Unit","published_at":"2020-02-07T23:50:54.000Z","date":"2020-02-06","kind":"grant","acquired":true,"shares":7897,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F8","text":"Each Restricted Stock Unit represents a contingent right to receive one share of the Issuer Common Stock."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F9","text":"The Restricted Stock Units will vest annually at 1/4 of the units vesting on each of February 6, 2021, February 6, 2022, February 6, 2023, and February 6, 2024."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F9","text":"The Restricted Stock Units will vest annually at 1/4 of the units vesting on each of February 6, 2021, February 6, 2022, February 6, 2023, and February 6, 2024."}],"balance_after":7897,"derivative":{"underlying":"Common Stock","underlying_shares":7897},"source":{"system":"sec-edgar","filing":"0001209191-20-007691","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/914475/000120919120007691/doc4.xml","form_type":"4"}},{"id":3285295,"issuer":{"id":2655,"kind":"organization","name":"NEUROCRINE BIOSCIENCES INC","symbol":"NBIX"},"owners":[{"id":130927,"kind":"person","name":"Grigoriadis Dimitri E.","position":1,"cik":"0001423838","reported_name":"Grigoriadis Dimitri E.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Research Officer"}}],"security":"Stock Option","published_at":"2020-02-07T23:50:54.000Z","date":"2020-02-06","kind":"grant","acquired":true,"shares":49844,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F7","text":"Represents option of which 1/48th of the shares underlying the option becomes vested and exercisable on March 6, 2020 and an additional 1/48th of the shares underlying the option becomes vested and exercisable each month thereafter."}],"balance_after":49844,"derivative":{"exercise_price":102.9,"expiration_date":"2030-02-06","underlying":"Common Stock","underlying_shares":49844},"source":{"system":"sec-edgar","filing":"0001209191-20-007691","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/914475/000120919120007691/doc4.xml","form_type":"4"}},{"id":3285294,"issuer":{"id":2655,"kind":"organization","name":"NEUROCRINE BIOSCIENCES INC","symbol":"NBIX"},"owners":[{"id":130927,"kind":"person","name":"Grigoriadis Dimitri E.","position":1,"cik":"0001423838","reported_name":"Grigoriadis Dimitri E.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Research Officer"}}],"security":"Common Stock","published_at":"2020-02-07T23:50:54.000Z","date":"2020-02-06","kind":"sale","acquired":false,"shares":803,"price":101.4398,"value":81456.1594,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F5","text":"Sale of 803 shares of common stock issued upon vesting of 1,525 restricted stock units on February 6, 2020 to cover payroll and withholding taxes, with the balance of the shares (722) maintained by the Reporting Person; the disposition reported in this Form 4 was effected by a broker pursuant to instructions set forth in a Rule 10b5-1 trading plan adopted by the Reporting Person at least 60 days prior to the transaction date in Box 2 above. Additionally, Issuer policy restricts the Reporting Person from amending or otherwise modifying any 10b5-1 trading plan subsequent to adoption of the plan."},{"field":"price","element":"transactionPricePerShare","label":"F6","text":"Represents a weighted average sales price per share. These shares were sold in multiple transactions at prices ranging from $99.67 to $103.03. The Reporting Person has provided to the issuer, and will provide to any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range."}],"balance_after":110587,"source":{"system":"sec-edgar","filing":"0001209191-20-007691","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/914475/000120919120007691/doc4.xml","form_type":"4"}},{"id":3285293,"issuer":{"id":2655,"kind":"organization","name":"NEUROCRINE BIOSCIENCES INC","symbol":"NBIX"},"owners":[{"id":130927,"kind":"person","name":"Grigoriadis Dimitri E.","position":1,"cik":"0001423838","reported_name":"Grigoriadis Dimitri E.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Research Officer"}}],"security":"Common Stock","published_at":"2020-02-07T23:50:54.000Z","date":"2020-02-05","kind":"sale","acquired":false,"shares":605,"price":103.1493,"value":62405.3265,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F3","text":"Sale of 605 shares of common stock issued upon vesting of 1,150 restricted stock units on February 5, 2020 to cover payroll and withholding taxes, with the balance of the shares (545) maintained by the Reporting Person; the disposition reported in this Form 4 was effected by a broker pursuant to instructions set forth in a Rule 10b5-1 trading plan adopted by the Reporting Person at least 60 days prior to the transaction date in Box 2 above. Additionally, Issuer policy restricts the Reporting Person from amending or otherwise modifying any 10b5-1 trading plan subsequent to adoption of the plan."},{"field":"price","element":"transactionPricePerShare","label":"F4","text":"Represents a weighted average sales price per share. These shares were sold in multiple transactions at prices ranging from $101.98 to $104.20. The Reporting Person has provided to the issuer, and will provide to any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range."}],"balance_after":109865,"source":{"system":"sec-edgar","filing":"0001209191-20-007691","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/914475/000120919120007691/doc4.xml","form_type":"4"}},{"id":3285292,"issuer":{"id":2655,"kind":"organization","name":"NEUROCRINE BIOSCIENCES INC","symbol":"NBIX"},"owners":[{"id":130927,"kind":"person","name":"Grigoriadis Dimitri E.","position":1,"cik":"0001423838","reported_name":"Grigoriadis Dimitri E.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Research Officer"}}],"security":"Common Stock","published_at":"2020-02-07T23:50:54.000Z","date":"2020-02-05","kind":"sale","acquired":false,"shares":1013,"price":103.1481,"value":104489.0253,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Sale of 1,013 shares of common stock issued upon vesting of 1,925 restricted stock units on February 5, 2020 to cover payroll and withholding taxes, with the balance of the shares (912) maintained by the Reporting Person; the disposition reported in this Form 4 was effected by a broker pursuant to instructions set forth in a Rule 10b5-1 trading plan adopted by the Reporting Person at least 60 days prior to the transaction date in Box 2 above. Additionally, Issuer policy restricts the Reporting Person from amending or otherwise modifying any 10b5-1 trading plan subsequent to adoption of the plan."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"Represents a weighted average sales price per share. These shares were sold in multiple transactions at prices ranging from $101.90 to $105.04 The Reporting Person has provided to the issuer, and will provide to any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range."}],"balance_after":109320,"source":{"system":"sec-edgar","filing":"0001209191-20-007691","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/914475/000120919120007691/doc4.xml","form_type":"4"}},{"id":3366799,"issuer":{"id":2655,"kind":"organization","name":"NEUROCRINE BIOSCIENCES INC","symbol":"NBIX"},"owners":[{"id":130927,"kind":"person","name":"Grigoriadis Dimitri E.","position":1,"cik":"0001423838","reported_name":"Grigoriadis Dimitri E.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Research Officer"}}],"security":"Non-Qualified Stock Option","published_at":"2019-11-19T22:37:31.000Z","date":"2019-11-18","kind":"exercise","acquired":false,"shares":5000,"price":35.99,"value":179950.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"Option granted February 05, 2016 and vests monthly over four years."}],"balance_after":28830,"derivative":{"exercise_price":35.99,"expiration_date":"2026-02-05","underlying":"Common Stock","underlying_shares":5000},"source":{"system":"sec-edgar","filing":"0001209191-19-057272","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/914475/000120919119057272/doc4.xml","form_type":"4"}},{"id":3366798,"issuer":{"id":2655,"kind":"organization","name":"NEUROCRINE BIOSCIENCES INC","symbol":"NBIX"},"owners":[{"id":130927,"kind":"person","name":"Grigoriadis Dimitri E.","position":1,"cik":"0001423838","reported_name":"Grigoriadis Dimitri E.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Research Officer"}}],"security":"Common Stock","published_at":"2019-11-19T22:37:31.000Z","date":"2019-11-18","kind":"sale","acquired":false,"shares":5000,"price":115.98,"value":579900.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The disposition reported in this Form 4 was effected by a broker pursuant to instructions set forth in a Rule 10b5-1 trading plan adopted by the Reporting Person at least 60 days prior to the transaction date in Box 2 above. Additionally, Issuer policy restricts the Reporting Person from amending or otherwise modifying any 10b5-1 trading plan subsequent to adoption of the plan."}],"balance_after":108408,"source":{"system":"sec-edgar","filing":"0001209191-19-057272","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/914475/000120919119057272/doc4.xml","form_type":"4"}},{"id":3366797,"issuer":{"id":2655,"kind":"organization","name":"NEUROCRINE BIOSCIENCES INC","symbol":"NBIX"},"owners":[{"id":130927,"kind":"person","name":"Grigoriadis Dimitri E.","position":1,"cik":"0001423838","reported_name":"Grigoriadis Dimitri E.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Research Officer"}}],"security":"Common Stock","published_at":"2019-11-19T22:37:31.000Z","date":"2019-11-18","kind":"exercise","acquired":true,"shares":5000,"price":35.99,"value":179950.0,"ownership":{"direct":true},"balance_after":113408,"source":{"system":"sec-edgar","filing":"0001209191-19-057272","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/914475/000120919119057272/doc4.xml","form_type":"4"}},{"id":3380860,"issuer":{"id":2655,"kind":"organization","name":"NEUROCRINE BIOSCIENCES INC","symbol":"NBIX"},"owners":[{"id":130927,"kind":"person","name":"Grigoriadis Dimitri E.","position":1,"cik":"0001423838","reported_name":"Grigoriadis Dimitri E.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Research Officer"}}],"security":"Non-Qualified Stock Option","published_at":"2019-11-05T21:37:29.000Z","date":"2019-11-01","kind":"exercise","acquired":false,"shares":10188,"price":32.99,"value":336102.12,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"Option granted February 3, 2015 and vested monthly over four years."}],"balance_after":0,"derivative":{"exercise_price":32.99,"expiration_date":"2025-02-03","underlying":"Common Stock","underlying_shares":10188},"source":{"system":"sec-edgar","filing":"0001209191-19-055228","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/914475/000120919119055228/doc4.xml","form_type":"4"}},{"id":3380859,"issuer":{"id":2655,"kind":"organization","name":"NEUROCRINE BIOSCIENCES INC","symbol":"NBIX"},"owners":[{"id":130927,"kind":"person","name":"Grigoriadis Dimitri E.","position":1,"cik":"0001423838","reported_name":"Grigoriadis Dimitri E.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Research Officer"}}],"security":"Common Stock","published_at":"2019-11-05T21:37:29.000Z","date":"2019-11-01","kind":"sale","acquired":false,"shares":10188,"price":100.3433,"value":1022297.5404,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The disposition reported in this Form 4 was effected by a broker pursuant to instructions set forth in a Rule 10b5-1 trading plan adopted by the Reporting Person at least 60 days prior to the transaction date in Box 2 above. Additionally, Issuer policy restricts the Reporting Person from amending or otherwise modifying any 10b5-1 trading plan subsequent to adoption of the plan."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"Represents a weighted average sales price per share. These shares were sold in multiple transactions at prices ranging from $100.00 to $100.71.The Reporting Person has provided to the issuer, and will provide to any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range."}],"balance_after":108408,"source":{"system":"sec-edgar","filing":"0001209191-19-055228","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/914475/000120919119055228/doc4.xml","form_type":"4"}},{"id":3380858,"issuer":{"id":2655,"kind":"organization","name":"NEUROCRINE BIOSCIENCES INC","symbol":"NBIX"},"owners":[{"id":130927,"kind":"person","name":"Grigoriadis Dimitri E.","position":1,"cik":"0001423838","reported_name":"Grigoriadis Dimitri E.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Research Officer"}}],"security":"Common Stock","published_at":"2019-11-05T21:37:29.000Z","date":"2019-11-01","kind":"exercise","acquired":true,"shares":10188,"price":32.99,"value":336102.12,"ownership":{"direct":true},"balance_after":118596,"source":{"system":"sec-edgar","filing":"0001209191-19-055228","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/914475/000120919119055228/doc4.xml","form_type":"4"}},{"id":3452574,"issuer":{"id":2655,"kind":"organization","name":"NEUROCRINE BIOSCIENCES INC","symbol":"NBIX"},"owners":[{"id":130927,"kind":"person","name":"Grigoriadis Dimitri E.","position":1,"cik":"0001423838","reported_name":"Grigoriadis Dimitri E.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Research Officer"}}],"security":"Non-Qualified Stock Option","published_at":"2019-07-31T23:12:46.000Z","date":"2019-07-30","kind":"exercise","acquired":false,"shares":50000,"price":32.99,"value":1649500.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"Option granted February 3, 2015 and vested monthly over four years."}],"balance_after":10188,"derivative":{"exercise_price":32.99,"expiration_date":"2025-02-03","underlying":"Common Stock","underlying_shares":50000},"source":{"system":"sec-edgar","filing":"0001209191-19-043916","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/914475/000120919119043916/doc4.xml","form_type":"4"}},{"id":3452573,"issuer":{"id":2655,"kind":"organization","name":"NEUROCRINE BIOSCIENCES INC","symbol":"NBIX"},"owners":[{"id":130927,"kind":"person","name":"Grigoriadis Dimitri E.","position":1,"cik":"0001423838","reported_name":"Grigoriadis Dimitri E.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Research Officer"}}],"security":"Common Stock","published_at":"2019-07-31T23:12:46.000Z","date":"2019-07-30","kind":"sale","acquired":false,"shares":10000,"price":94.3118,"value":943118.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The disposition reported in this Form 4 was effected by a broker pursuant to instructions set forth in a Rule 10b5-1 trading plan adopted by the Reporting Person at least 60 days prior to the transaction date in Box 2 above. Additionally, Issuer policy restricts the Reporting Person from amending or otherwise modifying any 10b5-1 trading plan subsequent to adoption of the plan."},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"Represents a weighted average sales price per share. These shares were sold in multiple transactions at prices ranging from $94.31 to $94.34. The Reporting Person has provided to the issuer, and will provide to any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range."}],"balance_after":108408,"source":{"system":"sec-edgar","filing":"0001209191-19-043916","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/914475/000120919119043916/doc4.xml","form_type":"4"}},{"id":3452572,"issuer":{"id":2655,"kind":"organization","name":"NEUROCRINE BIOSCIENCES INC","symbol":"NBIX"},"owners":[{"id":130927,"kind":"person","name":"Grigoriadis Dimitri E.","position":1,"cik":"0001423838","reported_name":"Grigoriadis Dimitri E.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Research Officer"}}],"security":"Common Stock","published_at":"2019-07-31T23:12:46.000Z","date":"2019-07-30","kind":"sale","acquired":false,"shares":50000,"price":92.6464,"value":4632320.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The disposition reported in this Form 4 was effected by a broker pursuant to instructions set forth in a Rule 10b5-1 trading plan adopted by the Reporting Person at least 60 days prior to the transaction date in Box 2 above. Additionally, Issuer policy restricts the Reporting Person from amending or otherwise modifying any 10b5-1 trading plan subsequent to adoption of the plan."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"Represents a weighted average sales price per share. These shares were sold in multiple transactions at prices ranging from $91.75 to $94.31. The Reporting Person has provided to the issuer, and will provide to any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range."}],"balance_after":118408,"source":{"system":"sec-edgar","filing":"0001209191-19-043916","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/914475/000120919119043916/doc4.xml","form_type":"4"}},{"id":3452571,"issuer":{"id":2655,"kind":"organization","name":"NEUROCRINE BIOSCIENCES INC","symbol":"NBIX"},"owners":[{"id":130927,"kind":"person","name":"Grigoriadis Dimitri E.","position":1,"cik":"0001423838","reported_name":"Grigoriadis Dimitri E.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Research Officer"}}],"security":"Common Stock","published_at":"2019-07-31T23:12:46.000Z","date":"2019-07-30","kind":"exercise","acquired":true,"shares":50000,"price":32.99,"value":1649500.0,"ownership":{"direct":true},"balance_after":168408,"source":{"system":"sec-edgar","filing":"0001209191-19-043916","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/914475/000120919119043916/doc4.xml","form_type":"4"}},{"id":3526618,"issuer":{"id":2655,"kind":"organization","name":"NEUROCRINE BIOSCIENCES INC","symbol":"NBIX"},"owners":[{"id":130927,"kind":"person","name":"Grigoriadis Dimitri E.","position":1,"cik":"0001423838","reported_name":"Grigoriadis Dimitri E.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Research Officer"}}],"security":"Common Stock","published_at":"2019-05-15T23:24:33.000Z","date":"2019-05-13","kind":"sale","acquired":false,"shares":1657,"price":75.4419,"value":125007.2283,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The disposition reported in this Form 4 was effected by a broker pursuant to instructions set forth in a Rule 10b5-1 trading plan adopted by the Reporting Person at least 90 days prior to the transaction date in Box 2 above. Additionally, Issuer policy restricts the Reporting Person from amending or otherwise modifying any 10b5-1 trading plan subsequent to adoption of the plan."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"Represents a weighted average sales price per share. These shares were sold in multiple transactions at prices ranging from $74.33 to $76.95. The Reporting Person has provided to the issuer, and will provide to any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range."}],"balance_after":118408,"source":{"system":"sec-edgar","filing":"0001209191-19-030173","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/914475/000120919119030173/doc4.xml","form_type":"4"}},{"id":3669084,"issuer":{"id":2655,"kind":"organization","name":"NEUROCRINE BIOSCIENCES INC","symbol":"NBIX"},"owners":[{"id":130927,"kind":"person","name":"Grigoriadis Dimitri E.","position":1,"cik":"0001423838","reported_name":"Grigoriadis Dimitri E.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Research Officer"}}],"security":"Restricted Stock Unit","published_at":"2019-02-08T22:09:45.000Z","date":"2019-02-07","kind":"grant","acquired":true,"shares":9254,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F4","text":"Each Restricted Stock Unit represents a contingent right to receive one share of the Issuer Common Stock."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F5","text":"The Restricted Stock Units will vest annually at 1/4 of the units vesting on each of February 7, 2020, February 7, 2021, February 7, 2022, and February 7, 2023."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F5","text":"The Restricted Stock Units will vest annually at 1/4 of the units vesting on each of February 7, 2020, February 7, 2021, February 7, 2022, and February 7, 2023."}],"balance_after":9254,"derivative":{"underlying":"Common Stock","underlying_shares":9254},"source":{"system":"sec-edgar","filing":"0001209191-19-008638","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/914475/000120919119008638/doc4.xml","form_type":"4"}},{"id":3669083,"issuer":{"id":2655,"kind":"organization","name":"NEUROCRINE BIOSCIENCES INC","symbol":"NBIX"},"owners":[{"id":130927,"kind":"person","name":"Grigoriadis Dimitri E.","position":1,"cik":"0001423838","reported_name":"Grigoriadis Dimitri E.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Research Officer"}}],"security":"Stock Option","published_at":"2019-02-08T22:09:45.000Z","date":"2019-02-07","kind":"grant","acquired":true,"shares":50005,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"Represents option of which 1/48th of the shares underlying the option becomes vested and exercisable on March 7, 2019 and an additional 1/48th of the shares underlying the option becomes vested and excercisable each month thereafter."}],"balance_after":50005,"derivative":{"exercise_price":81.05,"expiration_date":"2029-02-07","underlying":"Common Stock","underlying_shares":50005},"source":{"system":"sec-edgar","filing":"0001209191-19-008638","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/914475/000120919119008638/doc4.xml","form_type":"4"}},{"id":3669082,"issuer":{"id":2655,"kind":"organization","name":"NEUROCRINE BIOSCIENCES INC","symbol":"NBIX"},"owners":[{"id":130927,"kind":"person","name":"Grigoriadis Dimitri E.","position":1,"cik":"0001423838","reported_name":"Grigoriadis Dimitri E.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Research Officer"}}],"security":"Common Stock","published_at":"2019-02-08T22:09:45.000Z","date":"2019-02-06","kind":"sale","acquired":false,"shares":531,"price":84.0331,"value":44621.5761,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Sale of 531 shares of common stock issued upon vesting of 1,525 restricted stock units on February 6, 2019 to cover payroll and withholding taxes, with the balance of the shares (994) maintained by the Reporting Person; the disposition reported in this Form 4 was effected by a broker pursuant to instructions set forth in a Rule 10b5-1 trading plan adopted by the Reporting Person at least 90 days prior to the transaction date in Box 2 above. Additionally, Issuer policy restricts the Reporting Person from amending or otherwise modifying any 10b5-1 trading plan subsequent to adoption of the plan."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"Represents a weighted average sales price per share. These shares were sold in multiple transactions at prices ranging from $80.98 to $85.76. The Reporting Person has provided to the issuer, and will provide to any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range."}],"balance_after":120065,"source":{"system":"sec-edgar","filing":"0001209191-19-008638","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/914475/000120919119008638/doc4.xml","form_type":"4"}},{"id":3672756,"issuer":{"id":2655,"kind":"organization","name":"NEUROCRINE BIOSCIENCES INC","symbol":"NBIX"},"owners":[{"id":130927,"kind":"person","name":"Grigoriadis Dimitri E.","position":1,"cik":"0001423838","reported_name":"Grigoriadis Dimitri E.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Research Officer"}}],"security":"Common Stock","published_at":"2019-02-06T23:04:23.000Z","date":"2019-02-05","kind":"sale","acquired":false,"shares":401,"price":88.1667,"value":35354.8467,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F5","text":"Sale of 401 shares of common stock issued upon vesting of 1,150 restricted stock units on February 5, 2019 to cover payroll and withholding taxes, with the balance of the shares (749) maintained by the Reporting Person; the disposition reported in this Form 4 was effected by a broker pursuant to instructions set forth in a Rule 10b5-1 trading plan adopted by the Reporting Person at least 90 days prior to the transaction date in Box 2 above. Additionally, Issuer policy restricts the Reporting Person from amending or otherwise modifying any 10b5-1 trading plan subsequent to adoption of the plan."},{"field":"price","element":"transactionPricePerShare","label":"F4","text":"Represents a weighted average sales price per share. These shares were sold in multiple transactions at prices ranging from $87.34 to $88.79. The Reporting Person has provided to the issuer, and will provide to any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range."}],"balance_after":119071,"source":{"system":"sec-edgar","filing":"0001209191-19-007851","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/914475/000120919119007851/doc4.xml","form_type":"4"}},{"id":3672755,"issuer":{"id":2655,"kind":"organization","name":"NEUROCRINE BIOSCIENCES INC","symbol":"NBIX"},"owners":[{"id":130927,"kind":"person","name":"Grigoriadis Dimitri E.","position":1,"cik":"0001423838","reported_name":"Grigoriadis Dimitri E.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Research Officer"}}],"security":"Common Stock","published_at":"2019-02-06T23:04:23.000Z","date":"2019-02-05","kind":"sale","acquired":false,"shares":669,"price":88.1667,"value":58983.5223,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F3","text":"Sale of 669 shares of common stock issued upon vesting of 1,925 restricted stock units on February 5, 2019 to cover payroll and withholding taxes, with the balance of the shares (1,256) maintained by the Reporting Person; the disposition reported in this Form 4 was effected by a broker pursuant to instructions set forth in a Rule 10b5-1 trading plan adopted by the Reporting Person at least 90 days prior to the transaction date in Box 2 above. Additionally, Issuer policy restricts the Reporting Person from amending or otherwise modifying any 10b5-1 trading plan subsequent to adoption of the plan."},{"field":"price","element":"transactionPricePerShare","label":"F4","text":"Represents a weighted average sales price per share. These shares were sold in multiple transactions at prices ranging from $87.34 to $88.79. The Reporting Person has provided to the issuer, and will provide to any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range."}],"balance_after":118322,"source":{"system":"sec-edgar","filing":"0001209191-19-007851","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/914475/000120919119007851/doc4.xml","form_type":"4"}},{"id":3672754,"issuer":{"id":2655,"kind":"organization","name":"NEUROCRINE BIOSCIENCES INC","symbol":"NBIX"},"owners":[{"id":130927,"kind":"person","name":"Grigoriadis Dimitri E.","position":1,"cik":"0001423838","reported_name":"Grigoriadis Dimitri E.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Research Officer"}}],"security":"Common Stock","published_at":"2019-02-06T23:04:23.000Z","date":"2019-02-04","kind":"sale","acquired":false,"shares":1375,"price":88.1211,"value":121166.5125,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Sale of 1,375 shares of common stock issued upon vesting of 2,750 restricted stock units on February 4, 2019 to cover payroll and withholding taxes, with the balance of the shares (1,375) maintained by the Reporting Person; the disposition reported in this Form 4 was effected by a broker pursuant to instructions set forth in a Rule 10b5-1 trading plan adopted by the Reporting Person at least 90 days prior to the transaction date in Box 2 above. Additionally, Issuer policy restricts the Reporting Person from amending or otherwise modifying any 10b5-1 trading plan subsequent to adoption of the plan."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"Represents a weighted average sales price per share. These shares were sold in multiple transactions at prices ranging from $87.72 to $88.49. The Reporting Person has provided to the issuer, and will provide to any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range."}],"balance_after":117066,"source":{"system":"sec-edgar","filing":"0001209191-19-007851","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/914475/000120919119007851/doc4.xml","form_type":"4"}},{"id":3826111,"issuer":{"id":2655,"kind":"organization","name":"NEUROCRINE BIOSCIENCES INC","symbol":"NBIX"},"owners":[{"id":130927,"kind":"person","name":"Grigoriadis Dimitri E.","position":1,"cik":"0001423838","reported_name":"Grigoriadis Dimitri E.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Research Officer"}}],"security":"Incentive Stock Option","published_at":"2018-09-06T00:41:39.000Z","date":"2018-09-04","kind":"exercise","acquired":true,"shares":2102,"price":32.99,"value":69344.98,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"Option granted February 3, 2015 and vests monthly over four years."}],"balance_after":2710,"derivative":{"exercise_price":32.99,"expiration_date":"2025-02-03","underlying":"Common Stock","underlying_shares":2102},"source":{"system":"sec-edgar","filing":"0001209191-18-049721","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":8,"url":"https://www.sec.gov/Archives/edgar/data/914475/000120919118049721/doc4.xml","form_type":"4"}},{"id":3826110,"issuer":{"id":2655,"kind":"organization","name":"NEUROCRINE BIOSCIENCES INC","symbol":"NBIX"},"owners":[{"id":130927,"kind":"person","name":"Grigoriadis Dimitri E.","position":1,"cik":"0001423838","reported_name":"Grigoriadis Dimitri E.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Research Officer"}}],"security":"Incentive Stock Option","published_at":"2018-09-06T00:41:39.000Z","date":"2018-09-04","kind":"exercise","acquired":true,"shares":5978,"price":19.59,"value":117109.02,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"Option granted January 16, 2014 and vested monthly over four years."}],"balance_after":0,"derivative":{"exercise_price":19.59,"expiration_date":"2024-01-16","underlying":"Common Stock","underlying_shares":5978},"source":{"system":"sec-edgar","filing":"0001209191-18-049721","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":7,"url":"https://www.sec.gov/Archives/edgar/data/914475/000120919118049721/doc4.xml","form_type":"4"}},{"id":3826109,"issuer":{"id":2655,"kind":"organization","name":"NEUROCRINE BIOSCIENCES INC","symbol":"NBIX"},"owners":[{"id":130927,"kind":"person","name":"Grigoriadis Dimitri E.","position":1,"cik":"0001423838","reported_name":"Grigoriadis Dimitri E.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Research Officer"}}],"security":"Incentive Stock Option","published_at":"2018-09-06T00:41:39.000Z","date":"2018-09-04","kind":"exercise","acquired":true,"shares":11037,"price":8.65,"value":95470.05,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"Option granted January 10, 2013 and vested monthly over four years."}],"balance_after":0,"derivative":{"exercise_price":8.65,"expiration_date":"2023-01-10","underlying":"Common Stock","underlying_shares":11037},"source":{"system":"sec-edgar","filing":"0001209191-18-049721","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":6,"url":"https://www.sec.gov/Archives/edgar/data/914475/000120919118049721/doc4.xml","form_type":"4"}},{"id":3826108,"issuer":{"id":2655,"kind":"organization","name":"NEUROCRINE BIOSCIENCES INC","symbol":"NBIX"},"owners":[{"id":130927,"kind":"person","name":"Grigoriadis Dimitri E.","position":1,"cik":"0001423838","reported_name":"Grigoriadis Dimitri E.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Research Officer"}}],"security":"Incentive Stock Option","published_at":"2018-09-06T00:41:39.000Z","date":"2018-09-04","kind":"exercise","acquired":true,"shares":13632,"price":8.66,"value":118053.12,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"Option granted January 12, 2012 and vested monthly over four years."}],"balance_after":0,"derivative":{"exercise_price":8.66,"expiration_date":"2022-01-12","underlying":"Common Stock","underlying_shares":13632},"source":{"system":"sec-edgar","filing":"0001209191-18-049721","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/914475/000120919118049721/doc4.xml","form_type":"4"}},{"id":3826107,"issuer":{"id":2655,"kind":"organization","name":"NEUROCRINE BIOSCIENCES INC","symbol":"NBIX"},"owners":[{"id":130927,"kind":"person","name":"Grigoriadis Dimitri E.","position":1,"cik":"0001423838","reported_name":"Grigoriadis Dimitri E.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Research Officer"}}],"security":"Common Stock","published_at":"2018-09-06T00:41:39.000Z","date":"2018-09-04","kind":"exercise","acquired":true,"shares":2102,"price":32.99,"value":69344.98,"ownership":{"direct":true},"balance_after":115691,"source":{"system":"sec-edgar","filing":"0001209191-18-049721","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/914475/000120919118049721/doc4.xml","form_type":"4"}},{"id":3826106,"issuer":{"id":2655,"kind":"organization","name":"NEUROCRINE BIOSCIENCES INC","symbol":"NBIX"},"owners":[{"id":130927,"kind":"person","name":"Grigoriadis Dimitri E.","position":1,"cik":"0001423838","reported_name":"Grigoriadis Dimitri E.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Research Officer"}}],"security":"Common Stock","published_at":"2018-09-06T00:41:39.000Z","date":"2018-09-04","kind":"exercise","acquired":true,"shares":5978,"price":19.59,"value":117109.02,"ownership":{"direct":true},"balance_after":113589,"source":{"system":"sec-edgar","filing":"0001209191-18-049721","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/914475/000120919118049721/doc4.xml","form_type":"4"}},{"id":3826105,"issuer":{"id":2655,"kind":"organization","name":"NEUROCRINE BIOSCIENCES INC","symbol":"NBIX"},"owners":[{"id":130927,"kind":"person","name":"Grigoriadis Dimitri E.","position":1,"cik":"0001423838","reported_name":"Grigoriadis Dimitri E.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Research Officer"}}],"security":"Common Stock","published_at":"2018-09-06T00:41:39.000Z","date":"2018-09-04","kind":"exercise","acquired":true,"shares":11037,"price":8.65,"value":95470.05,"ownership":{"direct":true},"balance_after":107611,"source":{"system":"sec-edgar","filing":"0001209191-18-049721","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/914475/000120919118049721/doc4.xml","form_type":"4"}},{"id":3826104,"issuer":{"id":2655,"kind":"organization","name":"NEUROCRINE BIOSCIENCES INC","symbol":"NBIX"},"owners":[{"id":130927,"kind":"person","name":"Grigoriadis Dimitri E.","position":1,"cik":"0001423838","reported_name":"Grigoriadis Dimitri E.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Research Officer"}}],"security":"Common Stock","published_at":"2018-09-06T00:41:39.000Z","date":"2018-09-04","kind":"exercise","acquired":true,"shares":13632,"price":8.66,"value":118053.12,"ownership":{"direct":true},"balance_after":96574,"source":{"system":"sec-edgar","filing":"0001209191-18-049721","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/914475/000120919118049721/doc4.xml","form_type":"4"}},{"id":3853949,"issuer":{"id":2655,"kind":"organization","name":"NEUROCRINE BIOSCIENCES INC","symbol":"NBIX"},"owners":[{"id":130927,"kind":"person","name":"Grigoriadis Dimitri E.","position":1,"cik":"0001423838","reported_name":"Grigoriadis Dimitri E.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Research Officer"}}],"security":"Non-Qualified Stock Option","published_at":"2018-08-03T20:07:45.000Z","date":"2018-08-01","kind":"exercise","acquired":true,"shares":23022,"price":19.59,"value":451000.98,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"Option granted January 6, 2014 and vested monthly over four years."}],"balance_after":0,"derivative":{"exercise_price":19.59,"expiration_date":"2024-01-16","underlying":"Common Stock","underlying_shares":23022},"source":{"system":"sec-edgar","filing":"0001209191-18-045264","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/914475/000120919118045264/doc4.xml","form_type":"4"}},{"id":3853948,"issuer":{"id":2655,"kind":"organization","name":"NEUROCRINE BIOSCIENCES INC","symbol":"NBIX"},"owners":[{"id":130927,"kind":"person","name":"Grigoriadis Dimitri E.","position":1,"cik":"0001423838","reported_name":"Grigoriadis Dimitri E.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Research Officer"}}],"security":"Common Stock","published_at":"2018-08-03T20:07:45.000Z","date":"2018-08-01","kind":"sale","acquired":false,"shares":23022,"price":110,"value":2532420.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The disposition reported in this Form 4 was effected by a broker pursuant to instructions set forth in a Rule 10b5-1 trading plan adopted by the Reporting Person at least 90 days prior to the transaction date in Box 2 above. Additionally, Issuer policy restricts the Reporting Person from amending, canceling, suspending or otherwise modifying any 10b5-1 trading plan subsequent to adoption of the plan."}],"balance_after":82942,"source":{"system":"sec-edgar","filing":"0001209191-18-045264","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/914475/000120919118045264/doc4.xml","form_type":"4"}},{"id":3853947,"issuer":{"id":2655,"kind":"organization","name":"NEUROCRINE BIOSCIENCES INC","symbol":"NBIX"},"owners":[{"id":130927,"kind":"person","name":"Grigoriadis Dimitri E.","position":1,"cik":"0001423838","reported_name":"Grigoriadis Dimitri E.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Research Officer"}}],"security":"Common Stock","published_at":"2018-08-03T20:07:45.000Z","date":"2018-08-01","kind":"exercise","acquired":true,"shares":23022,"price":19.59,"value":451000.98,"ownership":{"direct":true},"balance_after":105964,"source":{"system":"sec-edgar","filing":"0001209191-18-045264","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/914475/000120919118045264/doc4.xml","form_type":"4"}},{"id":3886467,"issuer":{"id":2655,"kind":"organization","name":"NEUROCRINE BIOSCIENCES INC","symbol":"NBIX"},"owners":[{"id":130927,"kind":"person","name":"Grigoriadis Dimitri E.","position":1,"cik":"0001423838","reported_name":"Grigoriadis Dimitri E.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Research Officer"}}],"security":"Non-Qualified Stock Option","published_at":"2018-06-21T22:16:23.000Z","date":"2018-06-20","kind":"exercise","acquired":false,"shares":23000,"price":19.59,"value":450570.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"Represents option which vested 1/4 upon anniversary of grant (1/16/2015), thereafter vested in equal monthly installments over the following three years such that the entire award was fully vested at 12/16/2017."}],"balance_after":23022,"derivative":{"exercise_price":19.59,"expiration_date":"2024-01-16","underlying":"Common Stock","underlying_shares":23000},"source":{"system":"sec-edgar","filing":"0001209191-18-039022","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/914475/000120919118039022/doc4.xml","form_type":"4"}},{"id":3886466,"issuer":{"id":2655,"kind":"organization","name":"NEUROCRINE BIOSCIENCES INC","symbol":"NBIX"},"owners":[{"id":130927,"kind":"person","name":"Grigoriadis Dimitri E.","position":1,"cik":"0001423838","reported_name":"Grigoriadis Dimitri E.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Research Officer"}}],"security":"Common Stock","published_at":"2018-06-21T22:16:23.000Z","date":"2018-06-20","kind":"sale","acquired":false,"shares":23000,"price":105,"value":2415000.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The disposition reported in this Form 4 was effected by a broker pursuant to instructions set forth in a Rule 10b5-1 trading plan adopted by the Reporting Person at least 90 days prior to the transaction date in Box 2 above. Additionally, Issuer policy restricts the Reporting Person from amending, canceling, suspending or otherwise modifying any 10b5-1 trading plan subsequent to adoption of the plan."}],"balance_after":82942,"source":{"system":"sec-edgar","filing":"0001209191-18-039022","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/914475/000120919118039022/doc4.xml","form_type":"4"}},{"id":3886465,"issuer":{"id":2655,"kind":"organization","name":"NEUROCRINE BIOSCIENCES INC","symbol":"NBIX"},"owners":[{"id":130927,"kind":"person","name":"Grigoriadis Dimitri E.","position":1,"cik":"0001423838","reported_name":"Grigoriadis Dimitri E.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Research Officer"}}],"security":"Common Stock","published_at":"2018-06-21T22:16:23.000Z","date":"2018-06-20","kind":"exercise","acquired":true,"shares":23000,"price":19.59,"value":450570.0,"ownership":{"direct":true},"balance_after":105942,"source":{"system":"sec-edgar","filing":"0001209191-18-039022","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/914475/000120919118039022/doc4.xml","form_type":"4"}},{"id":3892995,"issuer":{"id":2655,"kind":"organization","name":"NEUROCRINE BIOSCIENCES INC","symbol":"NBIX"},"owners":[{"id":130927,"kind":"person","name":"Grigoriadis Dimitri E.","position":1,"cik":"0001423838","reported_name":"Grigoriadis Dimitri E.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Research Officer"}}],"security":"Non-Qualified Stock Option","published_at":"2018-06-15T20:44:53.000Z","date":"2018-06-14","kind":"exercise","acquired":false,"shares":23000,"price":19.59,"value":450570.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F5","text":"Represents option which vests 1/4 upon anniversary of grant (1/16/2015), thereafter vesting in equal monthly installments over the following three years such that the entire award is fully vested at 12/16/2017."}],"balance_after":46022,"derivative":{"exercise_price":19.59,"expiration_date":"2024-01-16","underlying":"Common Stock","underlying_shares":23000},"source":{"system":"sec-edgar","filing":"0001209191-18-038093","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":8,"url":"https://www.sec.gov/Archives/edgar/data/914475/000120919118038093/doc4.xml","form_type":"4"}},{"id":3892994,"issuer":{"id":2655,"kind":"organization","name":"NEUROCRINE BIOSCIENCES INC","symbol":"NBIX"},"owners":[{"id":130927,"kind":"person","name":"Grigoriadis Dimitri E.","position":1,"cik":"0001423838","reported_name":"Grigoriadis Dimitri E.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Research Officer"}}],"security":"Non-Qualified Stock Option","published_at":"2018-06-15T20:44:53.000Z","date":"2018-06-13","kind":"exercise","acquired":false,"shares":63963,"price":8.65,"value":553279.95,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"Represents option which vests 1/4 upon anniversary of grant (1/10/2014), thereafter vesting in equal monthly installments over the following three years such that the entire award is fully vested at 12/10/2016."}],"balance_after":0,"derivative":{"exercise_price":8.65,"expiration_date":"2023-01-10","underlying":"Common Stock","underlying_shares":63963},"source":{"system":"sec-edgar","filing":"0001209191-18-038093","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":7,"url":"https://www.sec.gov/Archives/edgar/data/914475/000120919118038093/doc4.xml","form_type":"4"}},{"id":3892993,"issuer":{"id":2655,"kind":"organization","name":"NEUROCRINE BIOSCIENCES INC","symbol":"NBIX"},"owners":[{"id":130927,"kind":"person","name":"Grigoriadis Dimitri E.","position":1,"cik":"0001423838","reported_name":"Grigoriadis Dimitri E.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Research Officer"}}],"security":"Common Stock","published_at":"2018-06-15T20:44:53.000Z","date":"2018-06-14","kind":"sale","acquired":false,"shares":2785,"price":100,"value":278500.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The disposition reported in this Form 4 was effected by a broker pursuant to instructions set forth in a Rule 10b5-1 trading plan adopted by the Reporting Person at least 90 days prior to the transaction date in Box 2 above. Additionally, Issuer policy restricts the Reporting Person from amending, canceling, suspending or otherwise modifying any 10b5-1 trading plan subsequent to adoption of the plan."}],"balance_after":82942,"source":{"system":"sec-edgar","filing":"0001209191-18-038093","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":6,"url":"https://www.sec.gov/Archives/edgar/data/914475/000120919118038093/doc4.xml","form_type":"4"}},{"id":3892992,"issuer":{"id":2655,"kind":"organization","name":"NEUROCRINE BIOSCIENCES INC","symbol":"NBIX"},"owners":[{"id":130927,"kind":"person","name":"Grigoriadis Dimitri E.","position":1,"cik":"0001423838","reported_name":"Grigoriadis Dimitri E.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Research Officer"}}],"security":"Common Stock","published_at":"2018-06-15T20:44:53.000Z","date":"2018-06-14","kind":"exercise","acquired":true,"shares":2785,"price":19.59,"value":54558.15,"ownership":{"direct":true},"balance_after":85727,"source":{"system":"sec-edgar","filing":"0001209191-18-038093","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/914475/000120919118038093/doc4.xml","form_type":"4"}},{"id":3892991,"issuer":{"id":2655,"kind":"organization","name":"NEUROCRINE BIOSCIENCES INC","symbol":"NBIX"},"owners":[{"id":130927,"kind":"person","name":"Grigoriadis Dimitri E.","position":1,"cik":"0001423838","reported_name":"Grigoriadis Dimitri E.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Research Officer"}}],"security":"Common Stock","published_at":"2018-06-15T20:44:53.000Z","date":"2018-06-13","kind":"sale","acquired":false,"shares":20215,"price":100.1126,"value":2023776.209,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The disposition reported in this Form 4 was effected by a broker pursuant to instructions set forth in a Rule 10b5-1 trading plan adopted by the Reporting Person at least 90 days prior to the transaction date in Box 2 above. Additionally, Issuer policy restricts the Reporting Person from amending, canceling, suspending or otherwise modifying any 10b5-1 trading plan subsequent to adoption of the plan."},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"Represents a weighted average sales price per share. These shares were sold in multiple transactions at prices ranging from $100.00 to $101.17. The Reporting Person has provided to the issuer, and will provide to any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range."}],"balance_after":82942,"source":{"system":"sec-edgar","filing":"0001209191-18-038093","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/914475/000120919118038093/doc4.xml","form_type":"4"}},{"id":3892990,"issuer":{"id":2655,"kind":"organization","name":"NEUROCRINE BIOSCIENCES INC","symbol":"NBIX"},"owners":[{"id":130927,"kind":"person","name":"Grigoriadis Dimitri E.","position":1,"cik":"0001423838","reported_name":"Grigoriadis Dimitri E.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Research Officer"}}],"security":"Common Stock","published_at":"2018-06-15T20:44:53.000Z","date":"2018-06-13","kind":"exercise","acquired":true,"shares":20215,"price":19.59,"value":396011.85,"ownership":{"direct":true},"balance_after":103157,"source":{"system":"sec-edgar","filing":"0001209191-18-038093","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/914475/000120919118038093/doc4.xml","form_type":"4"}},{"id":3892989,"issuer":{"id":2655,"kind":"organization","name":"NEUROCRINE BIOSCIENCES INC","symbol":"NBIX"},"owners":[{"id":130927,"kind":"person","name":"Grigoriadis Dimitri E.","position":1,"cik":"0001423838","reported_name":"Grigoriadis Dimitri E.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Research Officer"}}],"security":"Common Stock","published_at":"2018-06-15T20:44:53.000Z","date":"2018-06-13","kind":"sale","acquired":false,"shares":63963,"price":99.2521,"value":6348462.0723,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The disposition reported in this Form 4 was effected by a broker pursuant to instructions set forth in a Rule 10b5-1 trading plan adopted by the Reporting Person at least 90 days prior to the transaction date in Box 2 above. Additionally, Issuer policy restricts the Reporting Person from amending, canceling, suspending or otherwise modifying any 10b5-1 trading plan subsequent to adoption of the plan."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"Represents a weighted average sales price per share. These shares were sold in multiple transactions at prices ranging from $97.90 to $100.33. The Reporting Person has provided to the issuer, and will provide to any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range."}],"balance_after":82942,"source":{"system":"sec-edgar","filing":"0001209191-18-038093","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/914475/000120919118038093/doc4.xml","form_type":"4"}},{"id":3892988,"issuer":{"id":2655,"kind":"organization","name":"NEUROCRINE BIOSCIENCES INC","symbol":"NBIX"},"owners":[{"id":130927,"kind":"person","name":"Grigoriadis Dimitri E.","position":1,"cik":"0001423838","reported_name":"Grigoriadis Dimitri E.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Research Officer"}}],"security":"Common Stock","published_at":"2018-06-15T20:44:53.000Z","date":"2018-06-13","kind":"exercise","acquired":true,"shares":63963,"price":8.65,"value":553279.95,"ownership":{"direct":true},"balance_after":146905,"source":{"system":"sec-edgar","filing":"0001209191-18-038093","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/914475/000120919118038093/doc4.xml","form_type":"4"}},{"id":4064014,"issuer":{"id":2655,"kind":"organization","name":"NEUROCRINE BIOSCIENCES INC","symbol":"NBIX"},"owners":[{"id":130927,"kind":"person","name":"Grigoriadis Dimitri E.","position":1,"cik":"0001423838","reported_name":"Grigoriadis Dimitri E.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Research Officer"}}],"security":"Non-Qualified Stock Option","published_at":"2018-02-13T21:12:49.000Z","date":"2018-02-12","kind":"exercise","acquired":false,"shares":14593,"price":8.66,"value":126375.38,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"Option granted January 12, 2012 and vested monthly over four years."}],"balance_after":0,"derivative":{"exercise_price":8.66,"expiration_date":"2022-01-12","underlying":"Common Stock","underlying_shares":14593},"source":{"system":"sec-edgar","filing":"0001209191-18-009522","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":6,"url":"https://www.sec.gov/Archives/edgar/data/914475/000120919118009522/doc4.xml","form_type":"4"}},{"id":4064013,"issuer":{"id":2655,"kind":"organization","name":"NEUROCRINE BIOSCIENCES INC","symbol":"NBIX"},"owners":[{"id":130927,"kind":"person","name":"Grigoriadis Dimitri E.","position":1,"cik":"0001423838","reported_name":"Grigoriadis Dimitri E.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Research Officer"}}],"security":"Non-Qualified Stock Option","published_at":"2018-02-13T21:12:49.000Z","date":"2018-02-09","kind":"exercise","acquired":false,"shares":71775,"price":8.66,"value":621571.5,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"Option granted January 12, 2012 and vested monthly over four years."}],"balance_after":14593,"derivative":{"exercise_price":8.66,"expiration_date":"2022-01-12","underlying":"Common Stock","underlying_shares":71775},"source":{"system":"sec-edgar","filing":"0001209191-18-009522","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/914475/000120919118009522/doc4.xml","form_type":"4"}},{"id":4064012,"issuer":{"id":2655,"kind":"organization","name":"NEUROCRINE BIOSCIENCES INC","symbol":"NBIX"},"owners":[{"id":130927,"kind":"person","name":"Grigoriadis Dimitri E.","position":1,"cik":"0001423838","reported_name":"Grigoriadis Dimitri E.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Research Officer"}}],"security":"Common Stock","published_at":"2018-02-13T21:12:49.000Z","date":"2018-02-12","kind":"sale","acquired":false,"shares":14593,"price":80.0009,"value":1167453.1337,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The disposition reported in this Form 4 was effected by a broker pursuant to instructions set forth in a Rule 10b5-1 trading plan adopted by the Reporting Person at least 90 days prior to the transaction date in Box 2 above. Additionally, Issuer policy restricts the Reporting Person from amending, canceling, suspending or otherwise modifying any 10b5-1 trading plan subsequent to adoption of the plan."},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"Represents a weighted average sales price per share. These shares were sold in multiple transactions at prices ranging from $80.00 to $80.07. The Reporting Person has provided to the issuer, and will provide to any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range."}],"balance_after":82942,"source":{"system":"sec-edgar","filing":"0001209191-18-009522","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/914475/000120919118009522/doc4.xml","form_type":"4"}},{"id":4064011,"issuer":{"id":2655,"kind":"organization","name":"NEUROCRINE BIOSCIENCES INC","symbol":"NBIX"},"owners":[{"id":130927,"kind":"person","name":"Grigoriadis Dimitri E.","position":1,"cik":"0001423838","reported_name":"Grigoriadis Dimitri E.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Research Officer"}}],"security":"Common Stock","published_at":"2018-02-13T21:12:49.000Z","date":"2018-02-12","kind":"exercise","acquired":true,"shares":14593,"price":8.66,"value":126375.38,"ownership":{"direct":true},"balance_after":97535,"source":{"system":"sec-edgar","filing":"0001209191-18-009522","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/914475/000120919118009522/doc4.xml","form_type":"4"}},{"id":4064010,"issuer":{"id":2655,"kind":"organization","name":"NEUROCRINE BIOSCIENCES INC","symbol":"NBIX"},"owners":[{"id":130927,"kind":"person","name":"Grigoriadis Dimitri E.","position":1,"cik":"0001423838","reported_name":"Grigoriadis Dimitri E.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Research Officer"}}],"security":"Common Stock","published_at":"2018-02-13T21:12:49.000Z","date":"2018-02-09","kind":"sale","acquired":false,"shares":71775,"price":77.9759,"value":5596720.2225,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The disposition reported in this Form 4 was effected by a broker pursuant to instructions set forth in a Rule 10b5-1 trading plan adopted by the Reporting Person at least 90 days prior to the transaction date in Box 2 above. Additionally, Issuer policy restricts the Reporting Person from amending, canceling, suspending or otherwise modifying any 10b5-1 trading plan subsequent to adoption of the plan."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"Represents a weighted average sales price per share. These shares were sold in multiple transactions at prices ranging from $75.33 to $80.00. The Reporting Person has provided to the issuer, and will provide to any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range."}],"balance_after":82942,"source":{"system":"sec-edgar","filing":"0001209191-18-009522","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/914475/000120919118009522/doc4.xml","form_type":"4"}},{"id":4064009,"issuer":{"id":2655,"kind":"organization","name":"NEUROCRINE BIOSCIENCES INC","symbol":"NBIX"},"owners":[{"id":130927,"kind":"person","name":"Grigoriadis Dimitri E.","position":1,"cik":"0001423838","reported_name":"Grigoriadis Dimitri E.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Research Officer"}}],"security":"Common Stock","published_at":"2018-02-13T21:12:49.000Z","date":"2018-02-09","kind":"exercise","acquired":true,"shares":71775,"price":8.66,"value":621571.5,"ownership":{"direct":true},"balance_after":154717,"source":{"system":"sec-edgar","filing":"0001209191-18-009522","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/914475/000120919118009522/doc4.xml","form_type":"4"}},{"id":4072693,"issuer":{"id":2655,"kind":"organization","name":"NEUROCRINE BIOSCIENCES INC","symbol":"NBIX"},"owners":[{"id":130927,"kind":"person","name":"Grigoriadis Dimitri E.","position":1,"cik":"0001423838","reported_name":"Grigoriadis Dimitri E.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Research Officer"}}],"security":"Restricted Stock Unit","published_at":"2018-02-07T23:06:35.000Z","date":"2018-02-05","kind":"grant","acquired":true,"shares":12250,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F7","text":"Each Restricted Stock Unit represents a contingent right to receive one share of the Neurocrine Common Stock."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F9","text":"A portion of this grant will vest upon FDA approval of opicapone within a specified time period, and portions of this grant will vest upon achievement of specified revenue milestones within a specified time period."}],"balance_after":12250,"derivative":{"expiration_date":"2021-03-15","underlying":"Common Stock","underlying_shares":12250},"source":{"system":"sec-edgar","filing":"0001209191-18-008212","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":6,"url":"https://www.sec.gov/Archives/edgar/data/914475/000120919118008212/doc4.xml","form_type":"4"}},{"id":4072692,"issuer":{"id":2655,"kind":"organization","name":"NEUROCRINE BIOSCIENCES INC","symbol":"NBIX"},"owners":[{"id":130927,"kind":"person","name":"Grigoriadis Dimitri E.","position":1,"cik":"0001423838","reported_name":"Grigoriadis Dimitri E.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Research Officer"}}],"security":"Restricted Stock Unit","published_at":"2018-02-07T23:06:35.000Z","date":"2018-02-05","kind":"grant","acquired":true,"shares":4600,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F7","text":"Each Restricted Stock Unit represents a contingent right to receive one share of the Neurocrine Common Stock."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F8","text":"The Restricted Stock Units will vest annually at 1/4 of the units vesting on each of February 5, 2019, February 5, 2020, February 5, 2021, and February 5, 2022."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F8","text":"The Restricted Stock Units will vest annually at 1/4 of the units vesting on each of February 5, 2019, February 5, 2020, February 5, 2021, and February 5, 2022."}],"balance_after":4600,"derivative":{"underlying":"Common Stock","underlying_shares":4600},"source":{"system":"sec-edgar","filing":"0001209191-18-008212","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/914475/000120919118008212/doc4.xml","form_type":"4"}},{"id":4072691,"issuer":{"id":2655,"kind":"organization","name":"NEUROCRINE BIOSCIENCES INC","symbol":"NBIX"},"owners":[{"id":130927,"kind":"person","name":"Grigoriadis Dimitri E.","position":1,"cik":"0001423838","reported_name":"Grigoriadis Dimitri E.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Research Officer"}}],"security":"Stock Option","published_at":"2018-02-07T23:06:35.000Z","date":"2018-02-05","kind":"grant","acquired":true,"shares":26050,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F6","text":"Represents option of which 1/48th March 5, 2018 and an additional 1/48th of the shares underlying the option becomes vested and excercisable each month thereafter."}],"balance_after":26050,"derivative":{"exercise_price":81.49,"expiration_date":"2028-02-05","underlying":"Common Stock","underlying_shares":26050},"source":{"system":"sec-edgar","filing":"0001209191-18-008212","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/914475/000120919118008212/doc4.xml","form_type":"4"}},{"id":4072690,"issuer":{"id":2655,"kind":"organization","name":"NEUROCRINE BIOSCIENCES INC","symbol":"NBIX"},"owners":[{"id":130927,"kind":"person","name":"Grigoriadis Dimitri E.","position":1,"cik":"0001423838","reported_name":"Grigoriadis Dimitri E.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Research Officer"}}],"security":"Common Stock","published_at":"2018-02-07T23:06:35.000Z","date":"2018-02-06","kind":"tax_withholding","acquired":false,"shares":528,"price":82.48,"value":43549.44,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F5","text":"Payment of tax liability by withholding 528 shares of Common Stock incident to the vesting of a security issued in accordance with Rule 16b-3, with the balance of the shares (997) maintained by the Reporting Person."}],"balance_after":82942,"source":{"system":"sec-edgar","filing":"0001209191-18-008212","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/914475/000120919118008212/doc4.xml","form_type":"4"}},{"id":4072689,"issuer":{"id":2655,"kind":"organization","name":"NEUROCRINE BIOSCIENCES INC","symbol":"NBIX"},"owners":[{"id":130927,"kind":"person","name":"Grigoriadis Dimitri E.","position":1,"cik":"0001423838","reported_name":"Grigoriadis Dimitri E.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Research Officer"}}],"security":"Common Stock","published_at":"2018-02-07T23:06:35.000Z","date":"2018-02-05","kind":"sale","acquired":false,"shares":671,"price":83.2281,"value":55846.0551,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F3","text":"Sale of 671 shares of common stock issued upon vesting of 1,925 restricted stock units on February 5, 2018 to cover payroll and withholding taxes, with the balance of the shares (1,254) maintained by the Reporting Person; the disposition reported in this Form 4 was effected by a broker pursuant to instructions set forth in\na Rule 10b5-1 trading plan adopted by the Reporting Person at least 90 days prior to the transaction date in Box 2 above. Additionally, Issuer policy restricts the\nReporting Person from amending, canceling, suspending or otherwise modifying any 10b5-1 trading plan subsequent to adoption of the plan."},{"field":"price","element":"transactionPricePerShare","label":"F4","text":"Represents a weighted average sales price per share. These shares were sold in multiple transactions at prices ranging from $81.43 to $84.37. The Reporting Person has provided to the issuer, and will provide to any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range."}],"balance_after":81945,"source":{"system":"sec-edgar","filing":"0001209191-18-008212","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/914475/000120919118008212/doc4.xml","form_type":"4"}},{"id":4072688,"issuer":{"id":2655,"kind":"organization","name":"NEUROCRINE BIOSCIENCES INC","symbol":"NBIX"},"owners":[{"id":130927,"kind":"person","name":"Grigoriadis Dimitri E.","position":1,"cik":"0001423838","reported_name":"Grigoriadis Dimitri E.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Research Officer"}}],"security":"Common Stock","published_at":"2018-02-07T23:06:35.000Z","date":"2018-02-05","kind":"sale","acquired":false,"shares":1375,"price":83.0191,"value":114151.2625,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Sale of 1,375 shares of common stock issued upon vesting of 2,750 restricted stock units on February 5, 2018 to cover payroll and withholding taxes, with the balance of the shares (1,375) maintained by the Reporting Person; the disposition reported in this Form 4 was effected by a broker pursuant to instructions set forth in\na Rule 10b5-1 trading plan adopted by the Reporting Person at least 90 days prior to the transaction date in Box 2 above. Additionally, Issuer policy restricts the\nReporting Person from amending, canceling, suspending or otherwise modifying any 10b5-1 trading plan subsequent to adoption of the plan."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"Represents a weighted average sales price per share. These shares were sold in multiple transactions at prices ranging from $81.80 to $84.49. The Reporting Person has provided to the issuer, and will provide to any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range."}],"balance_after":80691,"source":{"system":"sec-edgar","filing":"0001209191-18-008212","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/914475/000120919118008212/doc4.xml","form_type":"4"}},{"id":4097028,"issuer":{"id":2655,"kind":"organization","name":"NEUROCRINE BIOSCIENCES INC","symbol":"NBIX"},"owners":[{"id":130927,"kind":"person","name":"Grigoriadis Dimitri E.","position":1,"cik":"0001423838","reported_name":"Grigoriadis Dimitri E.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Research Officer"}}],"security":"Common Stock","published_at":"2018-01-18T21:10:36.000Z","date":"2018-01-16","kind":"sale","acquired":false,"shares":1625,"price":79.1157,"value":128563.0125,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Sale of 1,625 shares of common stock issued upon vesting of 3,250 restricted stock units on January 16, 2018 to cover payroll and withholding taxes, with the balance of the shares (1,625) maintained by the Reporting Person; the disposition reported in this Form 4 was effected by a broker pursuant to instructions set forth in\na Rule 10b5-1 trading plan adopted by the Reporting Person at least 90 days prior to the transaction date in Box 2 above. Additionally, Issuer policy restricts the\nReporting Person from amending, canceling, suspending or otherwise modifying any 10b5-1 trading plan subsequent to adoption of the plan."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"Represents a weighted average sales price per share. These shares were sold in multiple transactions at prices ranging from $76.12 to $81.83. The Reporting Person has provided to the issuer, and will provide to any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range."}],"balance_after":79316,"source":{"system":"sec-edgar","filing":"0001209191-18-004244","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/914475/000120919118004244/doc4.xml","form_type":"4"}},{"id":4166449,"issuer":{"id":2655,"kind":"organization","name":"NEUROCRINE BIOSCIENCES INC","symbol":"NBIX"},"owners":[{"id":130927,"kind":"person","name":"Grigoriadis Dimitri E.","position":1,"cik":"0001423838","reported_name":"Grigoriadis Dimitri E.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Research Officer"}}],"security":"Common Stock","published_at":"2017-11-13T21:15:41.000Z","date":"2017-11-08","kind":"sale","acquired":false,"shares":30000,"price":74.5781,"value":2237343.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The disposition reported in this Form 4 was effected by a broker pursuant to instructions set forth in a Rule 10b5-1 trading plan adopted by the Reporting Person at least 90 days prior to the transaction date in Box 2 above. Additionally, Issuer policy restricts the Reporting Person from amending, canceling, suspending or otherwise modifying any 10b5-1 trading plan subsequent to adoption of the plan."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"Represents a weighted average sales price per share. These shares were sold in multiple transactions at prices ranging from $73.57 to $75.80. The Reporting Person has provided to the issuer, and will provide to any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range."}],"balance_after":77691,"source":{"system":"sec-edgar","filing":"0001209191-17-060286","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/914475/000120919117060286/doc4.xml","form_type":"4"}},{"id":4235661,"issuer":{"id":2655,"kind":"organization","name":"NEUROCRINE BIOSCIENCES INC","symbol":"NBIX"},"owners":[{"id":130927,"kind":"person","name":"Grigoriadis Dimitri E.","position":1,"cik":"0001423838","reported_name":"Grigoriadis Dimitri E.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Research Officer"}}],"security":"Incentive Stock Option","published_at":"2017-08-14T16:29:56.000Z","date":"2017-08-09","kind":"exercise","acquired":false,"shares":15354,"price":5.76,"value":88439.04,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"The option was granted August 25, 2011 and vested in 36 equal monthly installments beginning September 25, 2011."}],"balance_after":0,"derivative":{"exercise_price":5.76,"expiration_date":"2021-08-25","underlying":"Common Stock","underlying_shares":15354},"source":{"system":"sec-edgar","filing":"0001209191-17-048696","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/914475/000120919117048696/doc4.xml","form_type":"4"}},{"id":4235660,"issuer":{"id":2655,"kind":"organization","name":"NEUROCRINE BIOSCIENCES INC","symbol":"NBIX"},"owners":[{"id":130927,"kind":"person","name":"Grigoriadis Dimitri E.","position":1,"cik":"0001423838","reported_name":"Grigoriadis Dimitri E.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Research Officer"}}],"security":"Common Stock","published_at":"2017-08-14T16:29:56.000Z","date":"2017-08-09","kind":"sale","acquired":false,"shares":15354,"price":55,"value":844470.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The disposition reported in this Form 4 was effected by a broker pursuant to instructions set forth in a Rule 10b5-1 trading plan adopted by the Reporting Person at least 90 days prior to the transaction date in Box 3 above. Additionally, Issuer policy restricts the Reporting Person from amending, canceling, suspending or otherwise modifying any 10b5-1 trading plan subsequent to adoption of the plan."}],"balance_after":107691,"source":{"system":"sec-edgar","filing":"0001209191-17-048696","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/914475/000120919117048696/doc4.xml","form_type":"4"}},{"id":4235659,"issuer":{"id":2655,"kind":"organization","name":"NEUROCRINE BIOSCIENCES INC","symbol":"NBIX"},"owners":[{"id":130927,"kind":"person","name":"Grigoriadis Dimitri E.","position":1,"cik":"0001423838","reported_name":"Grigoriadis Dimitri E.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Research Officer"}}],"security":"Common Stock","published_at":"2017-08-14T16:29:56.000Z","date":"2017-08-09","kind":"exercise","acquired":true,"shares":15354,"price":5.76,"value":88439.04,"ownership":{"direct":true},"balance_after":123045,"source":{"system":"sec-edgar","filing":"0001209191-17-048696","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/914475/000120919117048696/doc4.xml","form_type":"4"}},{"id":4307076,"issuer":{"id":2655,"kind":"organization","name":"NEUROCRINE BIOSCIENCES INC","symbol":"NBIX"},"owners":[{"id":130927,"kind":"person","name":"Grigoriadis Dimitri E.","position":1,"cik":"0001423838","reported_name":"Grigoriadis Dimitri E.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Research Officer"}}],"security":"Common Stock","published_at":"2017-05-24T20:13:33.000Z","date":"2017-05-23","kind":"sale","acquired":false,"shares":10000,"price":53.39,"value":533900.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The disposition reported in this Form 4 was effected by a broker pursuant to instructions set forth in a Rule 10b5-1 trading plan adopted by the Reporting Person at least 90 days prior to the transaction date in Box 3 above. Additionally, Issuer policy restricts the Reporting Person from amending, canceling, suspending or otherwise modifying any 10b5-1 trading plan subsequent to adoption of the plan."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"Represents a weighted average sales price per share. These shares were sold in multiple transactions at prices ranging from $53.01 to $53.71. The Reporting Person has provided to the issuer, and will provide to any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range."}],"balance_after":107691,"source":{"system":"sec-edgar","filing":"0001209191-17-034910","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/914475/000120919117034910/doc4.xml","form_type":"4"}},{"id":4335991,"issuer":{"id":2655,"kind":"organization","name":"NEUROCRINE BIOSCIENCES INC","symbol":"NBIX"},"owners":[{"id":130927,"kind":"person","name":"Grigoriadis Dimitri E.","position":1,"cik":"0001423838","reported_name":"Grigoriadis Dimitri E.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Research Officer"}}],"security":"Common Stock","published_at":"2017-05-03T22:43:46.000Z","date":"2017-05-02","kind":"sale","acquired":false,"shares":10000,"price":55,"value":550000.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The disposition reported in this Form 4 was effected by a broker pursuant to instructions set forth in a Rule 10b5-1 trading plan adopted by the Reporting Person at least 90 days prior to the transaction date in Box 3 above. Additionally, Issuer policy restricts the Reporting Person from amending, canceling, suspending or otherwise modifying any 10b5-1 trading plan subsequent to adoption of the plan."}],"balance_after":117691,"source":{"system":"sec-edgar","filing":"0001209191-17-029801","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/914475/000120919117029801/doc4.xml","form_type":"4"}},{"id":4352926,"issuer":{"id":2655,"kind":"organization","name":"NEUROCRINE BIOSCIENCES INC","symbol":"NBIX"},"owners":[{"id":130927,"kind":"person","name":"Grigoriadis Dimitri E.","position":1,"cik":"0001423838","reported_name":"Grigoriadis Dimitri E.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Research Officer"}}],"security":"Common Stock","published_at":"2017-04-13T20:54:06.000Z","date":"2017-04-12","kind":"sale","acquired":false,"shares":204,"price":51.23,"value":10450.92,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Sale of 13,065 shares of common stock issued upon vesting of 25,000 performance restricted stock units on April 11, 2017 to cover withholding taxes, with the balance of the shares (11,935) maintained by the Reporting Person; the disposition reported in this Form 4 was effected by a broker pursuant to instructions set forth in a Rule 10b5-1 trading plan adopted by the Reporting Person at least 90 days prior to the transaction date in Box 3 above. Additionally, Issuer policy restricts the Reporting Person from amending, canceling, suspending or otherwise modifying any 10b5-1 trading plan subsequent to adoption of the plan."},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"Represents a weighted average sales price per share. These shares were sold in multiple transactions at prices ranging from $51.19 to $51.25. The Reporting Person has provided to the issuer, and will provide to any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range."}],"balance_after":127691,"source":{"system":"sec-edgar","filing":"0001209191-17-026881","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/914475/000120919117026881/doc4.xml","form_type":"4"}},{"id":4352925,"issuer":{"id":2655,"kind":"organization","name":"NEUROCRINE BIOSCIENCES INC","symbol":"NBIX"},"owners":[{"id":130927,"kind":"person","name":"Grigoriadis Dimitri E.","position":1,"cik":"0001423838","reported_name":"Grigoriadis Dimitri E.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Research Officer"}}],"security":"Common Stock","published_at":"2017-04-13T20:54:06.000Z","date":"2017-04-12","kind":"sale","acquired":false,"shares":12861,"price":50.41,"value":648323.01,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Sale of 13,065 shares of common stock issued upon vesting of 25,000 performance restricted stock units on April 11, 2017 to cover withholding taxes, with the balance of the shares (11,935) maintained by the Reporting Person; the disposition reported in this Form 4 was effected by a broker pursuant to instructions set forth in a Rule 10b5-1 trading plan adopted by the Reporting Person at least 90 days prior to the transaction date in Box 3 above. Additionally, Issuer policy restricts the Reporting Person from amending, canceling, suspending or otherwise modifying any 10b5-1 trading plan subsequent to adoption of the plan."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"Represents a weighted average sales price per share. These shares were sold in multiple transactions at prices ranging from $50.20 to $50.73. The Reporting Person has provided to the issuer, and will provide to any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range."}],"balance_after":127895,"source":{"system":"sec-edgar","filing":"0001209191-17-026881","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/914475/000120919117026881/doc4.xml","form_type":"4"}},{"id":4462343,"issuer":{"id":2655,"kind":"organization","name":"NEUROCRINE BIOSCIENCES INC","symbol":"NBIX"},"owners":[{"id":130927,"kind":"person","name":"Grigoriadis Dimitri E.","position":1,"cik":"0001423838","reported_name":"Grigoriadis Dimitri E.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Research Officer"}}],"security":"Restricted Stock Option","published_at":"2017-02-09T00:44:21.000Z","date":"2017-02-06","kind":"grant","acquired":true,"shares":6100,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F4","text":"Each Restricted Stock Unit represents a contingent right to receive one share of the Neurocrine Common Stock."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F5","text":"The Restricted Stock Units will vest annually at 1/4 of the units vesting on each of February 6, 2018, February 6, 2019, February 6, 2020, and February 6, 2021."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F5","text":"The Restricted Stock Units will vest annually at 1/4 of the units vesting on each of February 6, 2018, February 6, 2019, February 6, 2020, and February 6, 2021."}],"balance_after":6100,"derivative":{"underlying":"Common Stock","underlying_shares":6100},"source":{"system":"sec-edgar","filing":"0001209191-17-008917","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/914475/000120919117008917/doc4.xml","form_type":"4"}},{"id":4462342,"issuer":{"id":2655,"kind":"organization","name":"NEUROCRINE BIOSCIENCES INC","symbol":"NBIX"},"owners":[{"id":130927,"kind":"person","name":"Grigoriadis Dimitri E.","position":1,"cik":"0001423838","reported_name":"Grigoriadis Dimitri E.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Research Officer"}}],"security":"Stock Option","published_at":"2017-02-09T00:44:21.000Z","date":"2017-02-06","kind":"grant","acquired":true,"shares":51600,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"Represents option of which 1/48th of the shares underlying the option becomes vested and exercisable on March 6, 2017 and an additional 1/48th of the shares underlying the option becomes vested and excercisable each month thereafter."}],"balance_after":51600,"derivative":{"exercise_price":43.24,"expiration_date":"2027-02-06","underlying":"Common Stock","underlying_shares":51600},"source":{"system":"sec-edgar","filing":"0001209191-17-008917","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/914475/000120919117008917/doc4.xml","form_type":"4"}},{"id":4462341,"issuer":{"id":2655,"kind":"organization","name":"NEUROCRINE BIOSCIENCES INC","symbol":"NBIX"},"owners":[{"id":130927,"kind":"person","name":"Grigoriadis Dimitri E.","position":1,"cik":"0001423838","reported_name":"Grigoriadis Dimitri E.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Research Officer"}}],"security":"Common Stock","published_at":"2017-02-09T00:44:21.000Z","date":"2017-02-06","kind":"sale","acquired":false,"shares":727,"price":43.13,"value":31355.51,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Sale of 727 shares of common stock issued upon vesting of 1925 restricted stock units to cover withholding taxes with the balance of the shares (1198) maintained by the Reporting Person; the disposition reported in this Form 4 was effected by a broker pursuant to instructions set forth in a Rule 10b5-1 trading plan adopted by the Reporting Person at least 90 days prior to the transaction date in Box 3 above. Additionally, Issuer policy restricts the Reporting Person from amending, canceling, suspending or otherwise modifying any 10b5-1 trading plan subsequent to adoption of the plan."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"Represents a weighted average sales price per share. These shares were sold in multiple transactions at prices ranging from $42.69 to $43.41. The Reporting Person has provided to the issuer, and will provide to any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range."}],"balance_after":115756,"source":{"system":"sec-edgar","filing":"0001209191-17-008917","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/914475/000120919117008917/doc4.xml","form_type":"4"}},{"id":4466940,"issuer":{"id":2655,"kind":"organization","name":"NEUROCRINE BIOSCIENCES INC","symbol":"NBIX"},"owners":[{"id":130927,"kind":"person","name":"Grigoriadis Dimitri E.","position":1,"cik":"0001423838","reported_name":"Grigoriadis Dimitri E.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Research Officer"}}],"security":"Common Stock","published_at":"2017-02-07T00:17:27.000Z","date":"2017-02-03","kind":"sale","acquired":false,"shares":1375,"price":42.56,"value":58520.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Sale of 1,375 shares of common stock issued upon vesting of 2,750 restricted stock units on February 3, 2017 to cover payroll and withholding taxes, with the balance of the shares (1,375) maintained by the Reporting Person; the disposition reported in this Form 4 was effected by a broker pursuant to instructions set forth in a Rule 10b5-1 trading plan adopted by the Reporting Person at least 90 days prior to the transaction date in Box 3 above. Additionally, Issuer policy restricts the Reporting Person from amending, canceling, suspending or otherwise modifying any 10b5-1 trading plan subsequent to adoption of the plan."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"Represents a weighted average sales price per share. These shares were sold in multiple transactions at prices ranging from $41.80 to $43.31. The Reporting Person has provided to the issuer, and will provide to any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range."}],"balance_after":114558,"source":{"system":"sec-edgar","filing":"0001209191-17-008133","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/914475/000120919117008133/doc4.xml","form_type":"4"}}],"next_cursor":"2017-02-07T00:17:27.000000Z,4466940"}